<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7344648</article-id><article-id pub-id-type="doi">10.3390/antibiotics9060325</article-id><article-id pub-id-type="publisher-id">antibiotics-09-00325</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Revaluation of Plant-Derived Terpenes to Fight Antibiotic-Resistant Infections</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cappiello</surname><given-names>Floriana</given-names></name><xref ref-type="aff" rid="af1-antibiotics-09-00325">1</xref><xref ref-type="author-notes" rid="fn1-antibiotics-09-00325">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Loffredo</surname><given-names>Maria Rosa</given-names></name><xref ref-type="aff" rid="af1-antibiotics-09-00325">1</xref><xref ref-type="author-notes" rid="fn1-antibiotics-09-00325">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Del Plato</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="af2-antibiotics-09-00325">2</xref><xref ref-type="aff" rid="af3-antibiotics-09-00325">3</xref></contrib><contrib contrib-type="author"><name><surname>Cammarone</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="af2-antibiotics-09-00325">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1295-1084</contrib-id><name><surname>Casciaro</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="af3-antibiotics-09-00325">3</xref><xref rid="c1-antibiotics-09-00325" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Quaglio</surname><given-names>Deborah</given-names></name><xref ref-type="aff" rid="af2-antibiotics-09-00325">2</xref><xref rid="c1-antibiotics-09-00325" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5991-5868</contrib-id><name><surname>Mangoni</surname><given-names>Maria Luisa</given-names></name><xref ref-type="aff" rid="af1-antibiotics-09-00325">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8707-4333</contrib-id><name><surname>Botta</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="af2-antibiotics-09-00325">2</xref></contrib><contrib contrib-type="author"><name><surname>Ghirga</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="af3-antibiotics-09-00325">3</xref></contrib></contrib-group><aff id="af1-antibiotics-09-00325"><label>1</label>Laboratory affiliated to Pasteur Italia-Fondazione Cenci Bolognetti, Department of Biochemical Sciences, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy; <email>floriana.cappiello@uniroma1.it</email> (F.C.); <email>mariarosa.loffredo@uniroma1.it</email> (M.R.L.); <email>marialuisa.mangoni@uniroma1.it</email> (M.L.M.)</aff><aff id="af2-antibiotics-09-00325"><label>2</label>Department of Chemistry and Technology of Drugs, &#x0201c;Department of Excellence 2018&#x02212;2022&#x0201d;, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy; <email>cristina.delplato@uniroma1.it</email> (C.D.P.); <email>silvia.cammarone@uniroma1.it</email> (S.C.); <email>bruno.botta@uniroma1.it</email> (B.B.)</aff><aff id="af3-antibiotics-09-00325"><label>3</label>Center For Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, Viale Regina Elena 291, 00161 Rome, Italy; <email>francesca.ghirga@iit.it</email></aff><author-notes><corresp id="c1-antibiotics-09-00325"><label>*</label>Correspondence: <email>bruno.casciaro@iit.it</email> (B.C.); <email>deborah.quaglio@uniroma1.it</email> (D.Q.)</corresp><fn id="fn1-antibiotics-09-00325"><label>&#x02020;</label><p>These authors equally contributed to the work.</p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2020</year></pub-date><volume>9</volume><issue>6</issue><elocation-id>325</elocation-id><history><date date-type="received"><day>18</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>10</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The discovery of antibiotics has revolutionized the medicine and treatment of microbial infections. However, the current scenario has highlighted the difficulties in marketing new antibiotics and an exponential increase in the appearance of resistant strains. On the other hand, research in the field of drug-discovery has revaluated the potential of natural products as a unique source for new biologically active molecules and scaffolds for the medicinal chemistry. In this review, we first contextualized the worldwide problem of antibiotic resistance and the importance that natural products of plant origin acquire as a source of new lead compounds. We then focused on terpenes and their potential development as antimicrobials, highlighting those studies that showed an activity against conventional antibiotic-resistant strains.</p></abstract><kwd-group><kwd>antibiotic resistance</kwd><kwd>plant secondary metabolites</kwd><kwd>plant-derived natural products</kwd><kwd>terpenes</kwd><kwd>diterpenes</kwd><kwd>triterpenes</kwd><kwd>multidrug-resistant strains.</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibiotics-09-00325"><title>1. Introduction</title><p>The discovery of penicillin by Alexander Fleming (1881&#x02013;1955) drastically revolutionized modern medicine and represented the beginning of the antibiotic era that saved millions of lives from bacterial infections [<xref rid="B1-antibiotics-09-00325" ref-type="bibr">1</xref>]. Since then, according to the definition expressed by Selman Waksman, any small molecule, produced by a microbe, with antagonistic properties on the growth of other microbes was defined as &#x0201c;antibiotic&#x0201d; [<xref rid="B2-antibiotics-09-00325" ref-type="bibr">2</xref>]. During the &#x0201c;Antibiotic Golden Age&#x0201d; (1940&#x02013;1970), hundreds of molecules were isolated, characterized, classified and marketed [<xref rid="B3-antibiotics-09-00325" ref-type="bibr">3</xref>,<xref rid="B4-antibiotics-09-00325" ref-type="bibr">4</xref>,<xref rid="B5-antibiotics-09-00325" ref-type="bibr">5</xref>]. For decades, antibiotics were used as &#x0201c;wonder drugs&#x0201d; to combat microbes but also as prophylactic agents in the field of agriculture, fish industry and breeding. The massive use, in addition to a high rate of prescriptions, mismanagement in the form of self-medication or interruption of therapy, led to an exponential appearance of resistant bacterial infections and consequent failure of antibiotic therapies [<xref rid="B6-antibiotics-09-00325" ref-type="bibr">6</xref>,<xref rid="B7-antibiotics-09-00325" ref-type="bibr">7</xref>]. This was followed by a post-antibiotic era where the discovery of new compounds is still in sharp decline, together with a proportional rise in the appearance of resistant strains [<xref rid="B8-antibiotics-09-00325" ref-type="bibr">8</xref>,<xref rid="B9-antibiotics-09-00325" ref-type="bibr">9</xref>,<xref rid="B10-antibiotics-09-00325" ref-type="bibr">10</xref>,<xref rid="B11-antibiotics-09-00325" ref-type="bibr">11</xref>,<xref rid="B12-antibiotics-09-00325" ref-type="bibr">12</xref>]. The problem of antibiotic resistance is crucial and scientific research should not lag behind. Only in Europe, in fact, about 700 thousand cases of antibiotic-resistant infections provoke 33,000 deaths every year, with an estimated cost above &#x020ac;1.5 billion [<xref rid="B13-antibiotics-09-00325" ref-type="bibr">13</xref>]. However, it should be considered that an estimated $200 million is required for a molecule to reach commercialization, with the possible risk of a rapid development of resistance and consequent interruption of clinical development [<xref rid="B14-antibiotics-09-00325" ref-type="bibr">14</xref>]. Despite this, it is evident that new molecules with antimicrobial properties are urgently needed and nature represents the primary source of biologically active compounds, in agreement with Fleming&#x02019;s statement: &#x0201c;I did not invent penicillin. Nature did that. I only discovered it by accident&#x0201d; [<xref rid="B15-antibiotics-09-00325" ref-type="bibr">15</xref>]. In this review, we focus on the relevance of natural compounds from plants (plant-derived natural products, PDNPs) in the 21st century drug discovery, with emphasis to terpenes showing antimicrobial activities and that can represent promising candidates to fight multidrug-resistant (MDR) microbial infections.</p></sec><sec id="sec2-antibiotics-09-00325"><title>2. Antimicrobial Resistance</title><p>Biologically active molecules are defined as antimicrobials if they are able to inhibit growth or to kill certain or various classes of microorganisms. However, microorganisms have developed several mechanisms to circumvent the action of these antimicrobial compounds. In this context, it is worthwhile to specify the difference between antimicrobial resistance and persistence. Resistance to a given molecule is maintained from the mother cell to the daughter cells, unless mutations make them susceptible again [<xref rid="B16-antibiotics-09-00325" ref-type="bibr">16</xref>]. In comparison, persistence is defined as the ability of microbial cells to be recalcitrant to the antibiotic action, as they enter into a stationary phase of their growth (dormant cells). This leads to the inefficacy of the antibiotic agents since most of them act by inhibiting or interacting with specific metabolic processes that are not active in dormant cells [<xref rid="B17-antibiotics-09-00325" ref-type="bibr">17</xref>,<xref rid="B18-antibiotics-09-00325" ref-type="bibr">18</xref>]. It is also important to define the two major types of antimicrobial resistance: natural and acquired [<xref rid="B19-antibiotics-09-00325" ref-type="bibr">19</xref>,<xref rid="B20-antibiotics-09-00325" ref-type="bibr">20</xref>]. Natural resistance can be constantly expressed in the bacterial species (intrinsic resistance), whereas acquired resistance is expressed only upon exposure to an antimicrobial agent (induced resistance) [<xref rid="B21-antibiotics-09-00325" ref-type="bibr">21</xref>]. The reduced permeability of the outer membrane and the activity of efflux pumps are classic examples of intrinsic resistance [<xref rid="B22-antibiotics-09-00325" ref-type="bibr">22</xref>]. Acquired resistance occurs through acquisition of genetic material by means of transformation, conjugation, transposition (horizontal gene transfer) or by mutation in the chromosomal DNA [<xref rid="B23-antibiotics-09-00325" ref-type="bibr">23</xref>,<xref rid="B24-antibiotics-09-00325" ref-type="bibr">24</xref>]. Mutation of the drug target or in those genes involved in the regulation of drug transporters are examples of acquired resistance [<xref rid="B19-antibiotics-09-00325" ref-type="bibr">19</xref>].</p><sec><title>Mechanisms of Antimicrobial Resistance</title><p>Gram(+) and Gram(&#x02212;) bacteria possess and/or have developed several mechanisms of antimicrobial resistance that fall into five major categories (<xref ref-type="fig" rid="antibiotics-09-00325-f001">Figure 1</xref>):</p><p><italic>Limitation of drug uptake</italic>. Bacteria can be intrinsically resistant to a certain antimicrobial due to their structure and morphology. Lipopolysaccharide (LPS) in Gram(&#x02212;) bacteria, for example, provides a physical barrier that protects the cell from several groups of large molecules [<xref rid="B25-antibiotics-09-00325" ref-type="bibr">25</xref>]. In these bacteria, drugs are internalized through porin channels that generally allow the uptake of hydrophilic molecules. Mutations that change their selectivity or that reduce the number of expressed porins are the two major mechanisms of antimicrobial resistance [<xref rid="B26-antibiotics-09-00325" ref-type="bibr">26</xref>,<xref rid="B27-antibiotics-09-00325" ref-type="bibr">27</xref>]. Gram(+) bacteria, lacking outer membrane, possess a peptidoglycan cell wall and the restricting drug uptake is not as prevalent. However, pathogenic bacterial species, i.e., <italic>Staphylococcus aureus</italic>, have developed a mechanism which consists in thickening the cell wall to limit the amount of drug that enters the cell [<xref rid="B28-antibiotics-09-00325" ref-type="bibr">28</xref>,<xref rid="B29-antibiotics-09-00325" ref-type="bibr">29</xref>]. <italic>Mycoplasma</italic> spp., devoid of cell wall, are intrinsically resistant to antimicrobials (e.g., &#x003b2;-lactams and glycopeptides) that interfere with cell wall synthesis and regulation [<xref rid="B30-antibiotics-09-00325" ref-type="bibr">30</xref>].</p><p><italic>Drug inactivation.</italic> Bacteria can produce several enzymes or molecules that inactivate drugs by covalent binding or enzymatic processes. Firstly, common antibiotics (e.g., aminoglycosides, streptogramins, fluoroquinolones, chloramphenicol) could be inactivated by acetylation, phosphorylation or adenylation; secondly, hydrolyzation is the primary mechanism by which bacteria can inactivate &#x003b2;-lactam antibiotics (e.g., cephalosporins, penicillins and cephamycins). &#x003b2;-lactamases are the most common example: these enzymes provide resistance to &#x003b2;-lactam antibiotics by hydrolyzing a specific site in the &#x003b2;-lactam ring structure [<xref rid="B31-antibiotics-09-00325" ref-type="bibr">31</xref>]. Recently, &#x003b2;-lactamases were found to be active against carbapenems in Enterobacteriaceae (carbapenemases, i.e., <italic>Klebsiella pneumoniae</italic> carbapenemases and carbapenem-resistant enterobacteriaceae enzymes) [<xref rid="B31-antibiotics-09-00325" ref-type="bibr">31</xref>].</p><p><italic>Mutation/alteration of the drug target.</italic> The majority of antimicrobials have a specific mechanism of action against a specific cellular target and this is one of the reasons why bacteria are not susceptible to a certain class of molecules [<xref rid="B32-antibiotics-09-00325" ref-type="bibr">32</xref>]. Gram(+) strains, for instance, become resistant to &#x003b2;-lactam drugs via alteration of the penicillin-binding proteins, that are transpeptidases involved in the cell wall construction [<xref rid="B33-antibiotics-09-00325" ref-type="bibr">33</xref>]. <italic>S. aureus</italic> acquires resistance to the glycopeptide vancomycin by decreasing the binding ability of this molecule to the cell wall, as a consequence of a modification of the terminal d-Ala&#x02013;d-Ala moiety of the peptidoglycan precursor lipid II [<xref rid="B34-antibiotics-09-00325" ref-type="bibr">34</xref>].</p><p><italic>Drug efflux.</italic> Bacteria can eliminate internalized toxic substances through a mechanism involving efflux pumps, which can be constitutively expressed or overexpressed under certain conditions. Many of these pumps have the capability to transport different types of substances. They are properly named multi-drug efflux pumps [<xref rid="B35-antibiotics-09-00325" ref-type="bibr">35</xref>] and their increased number is generally associated to high-level of resistance to clinically significant bacterial infections [<xref rid="B36-antibiotics-09-00325" ref-type="bibr">36</xref>,<xref rid="B37-antibiotics-09-00325" ref-type="bibr">37</xref>].</p><p><italic>Biofilm formation.</italic> In conditions of environmental stress, scarcity of nutrients, presence of antimicrobial molecules, some bacterial species can switch from a motile to a sessile lifestyle, named biofilm. This is a bacterial community able to colonize abiotic (e.g., medical devices and implants [<xref rid="B38-antibiotics-09-00325" ref-type="bibr">38</xref>,<xref rid="B39-antibiotics-09-00325" ref-type="bibr">39</xref>,<xref rid="B40-antibiotics-09-00325" ref-type="bibr">40</xref>]) and biotic surfaces (e.g., human tissues [<xref rid="B41-antibiotics-09-00325" ref-type="bibr">41</xref>,<xref rid="B42-antibiotics-09-00325" ref-type="bibr">42</xref>,<xref rid="B43-antibiotics-09-00325" ref-type="bibr">43</xref>]). Biofilm formation is a strategy used by pathogenic bacteria to protect themselves from the external stressful conditions by producing a thick and sticky extracellular matrix which contains DNA, proteins and polysaccharides. In addition, biofilm cells enter into a slow division rate, which weakens the effect of antibiotic molecules targeting specific cellular processes. Thus, biofilms are often associated to chronic infections and molecules capable to disrupt these communities and/or to inhibit their formation are highly demanded [<xref rid="B44-antibiotics-09-00325" ref-type="bibr">44</xref>,<xref rid="B45-antibiotics-09-00325" ref-type="bibr">45</xref>].</p></sec></sec><sec id="sec3-antibiotics-09-00325"><title>3. Plant Derived Natural Products</title><p>The practice of using plants for medicinal purposes is thousands of years old. Since the earliest civilizations, plants have played a major role in medicine due to their variability and abundance of therapeutic agents [<xref rid="B46-antibiotics-09-00325" ref-type="bibr">46</xref>,<xref rid="B47-antibiotics-09-00325" ref-type="bibr">47</xref>]. Notably, the first manuscript that reports the use of medicinal plants dates back to 2600 BC; it describes a complex medical system, with the use of over 1000 medicinal plants in Mesopotamia [<xref rid="B48-antibiotics-09-00325" ref-type="bibr">48</xref>]. The &#x0201c;Ebers Papyrus&#x0201d; from about 1500 BC describes the usage of about 700 drugs (mainly plant-derived) in the Egyptian medicine, while traditional Chinese medicine has been extensively documented and nowadays it is still of reference [<xref rid="B48-antibiotics-09-00325" ref-type="bibr">48</xref>,<xref rid="B49-antibiotics-09-00325" ref-type="bibr">49</xref>,<xref rid="B50-antibiotics-09-00325" ref-type="bibr">50</xref>]. In the West, the tradition of medicinal plants has foundations in the culture of Greek and Roman civilizations, as proved by the compendiums written by Dioscorides and Pliny the Elder, respectively [<xref rid="B51-antibiotics-09-00325" ref-type="bibr">51</xref>]. However, until the 18th century AD, the use of plants in medicine has been based on empirical evidence. It was only with the first studies conducted by Anton von St&#x000f6;rck on poisonous herbs (i.e., colchicum and aconite) and by William Withering on foxglove, that the foundations of a scientific research on medicinal plants were laid [<xref rid="B52-antibiotics-09-00325" ref-type="bibr">52</xref>]. Rational drug discovery began in 1806 when Friedrich Sert&#x000fc;rner isolated a bioactive compound from the poppy plant, i.e., the alkaloid with analgesic and sleep-inducing effects and that he called &#x0201c;morphine&#x0201d; in honor of the Greek God of dreams, Morpheus. This induced a significant boost in the research and isolation of bioactive compounds from plants, as evidenced by the numerous discoveries of the following decades. In 1820, Runge isolated caffeine from <italic>Coffea arabica</italic>; in 1824 the anti-tussive agent codeine was isolated from poppy by Robiquet, while in 1848 the anti-spasmodic alkaloid papaverine was identified by Merck Fraz; in 1869, digoxin (digitalis) was isolated from <italic>Digitalis lanata</italic> by Nativelle [<xref rid="B53-antibiotics-09-00325" ref-type="bibr">53</xref>]. These discoveries led to an exponential growth of scientific and economic interest in the PDNPs which reaches up to the present day: &#x0223c;25% of the estimated 1.1 trillion US dollars invested in the pharmaceutical market annually, come from PDNPs [<xref rid="B53-antibiotics-09-00325" ref-type="bibr">53</xref>]. Thanks to computational and biological approaches it has been easier to proceed with the identification, selection and production of PDNPs which nowadays possess a renewed scientific and economic potential [<xref rid="B54-antibiotics-09-00325" ref-type="bibr">54</xref>,<xref rid="B55-antibiotics-09-00325" ref-type="bibr">55</xref>].</p><sec><title>Plant-Derived Drug Discovery: The Two Sides of the Coin</title><p>Plant-derived drug discovery is currently hindered by a series of scientific, social and economic factors that deserve to be analyzed in order to contextualize the actual scenario of the pharmaceutical market.</p><p><italic>Socio-economic factors</italic>. A main issue here is the access to starting materials. Initially, there is a process of correct identification and nomenclature that cannot be automated and requires experts in the field. These experts are also necessary for the correct collection, documentation and preparation of the investigated herbarium, but they are rather rare [<xref rid="B56-antibiotics-09-00325" ref-type="bibr">56</xref>,<xref rid="B57-antibiotics-09-00325" ref-type="bibr">57</xref>]. The isolation processes, albeit with high yield, lead to very low quantities of active compounds, thus requiring a very high amount of starting material. This is a crucial factor; many plants need precise habitats for their growth and optimal production of metabolites and have seasonal life cycles, making their harvest difficult to scale-up. Furthermore, the ecological balance of the belonging niche must be taken into consideration: in fact, it is important to evaluate the impact that a reduction in the number of plants in the niche can have on food chains and other living species. Finally, many plants grow only in certain regions and political factors must be taken into account for their harvest, such as wars, international relations between states, import/export laws [<xref rid="B56-antibiotics-09-00325" ref-type="bibr">56</xref>].</p><p><italic>Scientific factors</italic>. One of the most relevant concerns is undoubtedly the quality of the raw material. This is influenced by various conditions, including the time of harvest, the quality of the soil, possible environmental contamination as well as the type of processing and storage [<xref rid="B58-antibiotics-09-00325" ref-type="bibr">58</xref>]. Biologically active compounds often have a complex chemical structure, with numerous chiral centers and substituents containing oxygen, which make their synthesis difficult in the laboratory. The extracts obtained from natural samples have a high viscosity, can precipitate or aggregate easily, but, above all, they often consist of a mixture of bioactive compounds that makes biological activity tests of dubious interpretation [<xref rid="B59-antibiotics-09-00325" ref-type="bibr">59</xref>,<xref rid="B60-antibiotics-09-00325" ref-type="bibr">60</xref>,<xref rid="B61-antibiotics-09-00325" ref-type="bibr">61</xref>,<xref rid="B62-antibiotics-09-00325" ref-type="bibr">62</xref>,<xref rid="B63-antibiotics-09-00325" ref-type="bibr">63</xref>]. Another important issue is the mechanism of action that is not well defined yet, for some common compounds [<xref rid="B64-antibiotics-09-00325" ref-type="bibr">64</xref>].</p><p>Besides the challenges mentioned above, PDNPs are considered promising candidates for the development of new drugs, thanks to their intrinsic characteristics.</p><p>First, they represent a direct source of therapeutic agents or phytomedicines. Between 1981 and 2014, the Food and Drug Administration (FDA) approved 1562 new drugs from natural sources, of which 141 (9%) were botanical mixtures and 64 (4%) were unaltered natural products [<xref rid="B53-antibiotics-09-00325" ref-type="bibr">53</xref>]. According to recent analysis [<xref rid="B49-antibiotics-09-00325" ref-type="bibr">49</xref>,<xref rid="B53-antibiotics-09-00325" ref-type="bibr">53</xref>], the percentage of pharmacologically and phytochemically investigated plants is around 6% and 15% of the existing plant species, respectively. The plant kingdom can therefore be considered to be not fully explored and holds enormous potential. Furthermore, for some plants there is a well-documented millennial tradition of ethnopharmacology which represents an excellent starting point for more accurate scientific studies [<xref rid="B65-antibiotics-09-00325" ref-type="bibr">65</xref>,<xref rid="B66-antibiotics-09-00325" ref-type="bibr">66</xref>]. In addition, the advent of new techniques in separation, purification and characterization of novel compounds significantly improved the efficiency of these processes and, today, an important challenge is the generation of high-quality libraries of natural products that might allow the fast identification of lead compounds for drug discovery progression [<xref rid="B67-antibiotics-09-00325" ref-type="bibr">67</xref>,<xref rid="B68-antibiotics-09-00325" ref-type="bibr">68</xref>,<xref rid="B69-antibiotics-09-00325" ref-type="bibr">69</xref>,<xref rid="B70-antibiotics-09-00325" ref-type="bibr">70</xref>,<xref rid="B71-antibiotics-09-00325" ref-type="bibr">71</xref>,<xref rid="B72-antibiotics-09-00325" ref-type="bibr">72</xref>,<xref rid="B73-antibiotics-09-00325" ref-type="bibr">73</xref>,<xref rid="B74-antibiotics-09-00325" ref-type="bibr">74</xref>,<xref rid="B75-antibiotics-09-00325" ref-type="bibr">75</xref>]. Importantly, PDNPs serve as scaffold for the synthesis of libraries with several chemical structures and for the design of lead compounds with a desired biological activity or markers for a specific detection [<xref rid="B76-antibiotics-09-00325" ref-type="bibr">76</xref>,<xref rid="B77-antibiotics-09-00325" ref-type="bibr">77</xref>,<xref rid="B78-antibiotics-09-00325" ref-type="bibr">78</xref>]. These objectives can be achieved thanks to the contingent biological and computational approaches that can be used following one of these proposed models: the forward pharmacology or reverse pharmacology model. In the first case, the evidence of biological activity <italic>in vivo</italic> (i.e., antimicrobial assays, organ or tissue models, animal tests) are followed by in silico/in vitro analysis for target and mechanism identification. On the contrary, the more recent reverse pharmacology approach consists of an <italic>in silico/in vitro</italic> screening of a large libraries of compounds and the &#x0201c;hits&#x0201d; are selected for further <italic>in vivo</italic> characterization [<xref rid="B53-antibiotics-09-00325" ref-type="bibr">53</xref>].</p><p>In this review we will focus on an important class of secondary metabolites derived from plants, i.e., terpenes, that are under investigation for their antimicrobial activity, especially against antibiotic-resistant strains. The data we report in the next paragraphs were obtained from research groups all over the world and summarize the in vitro antimicrobial activity of these compounds, highlighting their high potentiality as new antimicrobials. This class of PDNPs has already been studied and commercialized for other important human diseases as proved by the high number of clinical trials (<xref rid="antibiotics-09-00325-t001" ref-type="table">Table 1</xref>) and marketed drugs (<xref rid="antibiotics-09-00325-t002" ref-type="table">Table 2</xref>).</p></sec></sec><sec id="sec4-antibiotics-09-00325"><title>4. Terpenes</title><p>Terpenes are the most numerous and structurally diverse class of natural products. These compounds are characterized by different carbon skeletons, but, despite structural differences, all terpenes are unified by a common biosynthetic pathway: the fusion of five-carbon isoprene units, the basic structural unit of terpenes. Since the last century, the biosynthetic process of terpenes was explained by the isoprene rule, which states that all terpenes derive from the ordered head-to-tail joining of isoprene units. A head-to-tail fusion is the most common; however, non-head-to-tail condensation of isoprene units also occurs [<xref rid="B90-antibiotics-09-00325" ref-type="bibr">90</xref>,<xref rid="B91-antibiotics-09-00325" ref-type="bibr">91</xref>]. It is useful to divide terpenes into classes according to the number of isoprene units they are biogenetically made of. They are classified as hemiterpenes (one isoprenoid unit); monoterpenes (two isoprenoid unites); sesquiterpenes (three isoprenoid unites); diterpenes (four isoprenoid unites); sesteterpenes (five isoprenoid unites); triterpenes (six isoprenoid unites) and tetraterpenes (eight isoprenoid unites) [<xref rid="B92-antibiotics-09-00325" ref-type="bibr">92</xref>]. As reported in the literature, several terpenes have been employed as important pharmaceutical agents with anti-inflammatory [<xref rid="B93-antibiotics-09-00325" ref-type="bibr">93</xref>], anti-viral [<xref rid="B94-antibiotics-09-00325" ref-type="bibr">94</xref>], anti-diabetic [<xref rid="B95-antibiotics-09-00325" ref-type="bibr">95</xref>], anti-tumor [<xref rid="B96-antibiotics-09-00325" ref-type="bibr">96</xref>] and antibacterial activities [<xref rid="B97-antibiotics-09-00325" ref-type="bibr">97</xref>]. Notably, terpenes have played a pivotal role in the fight against antibiotic resistance showing promising antibacterial potential against multi-resistant strains or acting as potentiators for antimicrobials by exhibiting synergistic effects [<xref rid="B98-antibiotics-09-00325" ref-type="bibr">98</xref>,<xref rid="B99-antibiotics-09-00325" ref-type="bibr">99</xref>,<xref rid="B100-antibiotics-09-00325" ref-type="bibr">100</xref>]. Due to their low yield from natural source, semi-synthetic and synthetic derivatives with improved biological properties have been developed [<xref rid="B101-antibiotics-09-00325" ref-type="bibr">101</xref>,<xref rid="B102-antibiotics-09-00325" ref-type="bibr">102</xref>]. The first step in studying medicinal plants is the preparation of plant samples to preserve the secondary metabolites prior to extraction. Compounds from different parts of a plant such as leaves, barks, roots, fruits and flowers can be extracted from fresh or dried plants material. Traditional methods such as maceration and Soxhlet extraction are widely employed in the studies reported in this review. First, the leaves are properly treated, dried and separated from foreign materials including soil, pebbles and other matters unsuitable for the solid-liquid extraction process. The fresh material is then air-dried, macerated usually by using a suitable solvent that, due to its polarity, is able to extract polar as well as less polar organic compounds. The obtained solution is the desired extract. In each case, extensive purifications of the obtained extract are performed by preparative Thin Layer Chromatography (TLC) or classic column chromatography or by advanced technology such as flash chromatography and High Performance Liquid Chromatography (HPLC) [<xref rid="B103-antibiotics-09-00325" ref-type="bibr">103</xref>,<xref rid="B104-antibiotics-09-00325" ref-type="bibr">104</xref>,<xref rid="B105-antibiotics-09-00325" ref-type="bibr">105</xref>,<xref rid="B106-antibiotics-09-00325" ref-type="bibr">106</xref>,<xref rid="B107-antibiotics-09-00325" ref-type="bibr">107</xref>,<xref rid="B108-antibiotics-09-00325" ref-type="bibr">108</xref>,<xref rid="B109-antibiotics-09-00325" ref-type="bibr">109</xref>,<xref rid="B110-antibiotics-09-00325" ref-type="bibr">110</xref>,<xref rid="B111-antibiotics-09-00325" ref-type="bibr">111</xref>,<xref rid="B112-antibiotics-09-00325" ref-type="bibr">112</xref>,<xref rid="B113-antibiotics-09-00325" ref-type="bibr">113</xref>,<xref rid="B114-antibiotics-09-00325" ref-type="bibr">114</xref>,<xref rid="B115-antibiotics-09-00325" ref-type="bibr">115</xref>,<xref rid="B116-antibiotics-09-00325" ref-type="bibr">116</xref>,<xref rid="B117-antibiotics-09-00325" ref-type="bibr">117</xref>,<xref rid="B118-antibiotics-09-00325" ref-type="bibr">118</xref>,<xref rid="B119-antibiotics-09-00325" ref-type="bibr">119</xref>,<xref rid="B120-antibiotics-09-00325" ref-type="bibr">120</xref>,<xref rid="B121-antibiotics-09-00325" ref-type="bibr">121</xref>,<xref rid="B122-antibiotics-09-00325" ref-type="bibr">122</xref>,<xref rid="B123-antibiotics-09-00325" ref-type="bibr">123</xref>,<xref rid="B124-antibiotics-09-00325" ref-type="bibr">124</xref>,<xref rid="B125-antibiotics-09-00325" ref-type="bibr">125</xref>,<xref rid="B126-antibiotics-09-00325" ref-type="bibr">126</xref>].</p><p>The structures and the purity of all terpenes reported in this review were unambiguously confirmed through nuclear magnetic resonance (NMR) spectroscopy, and by electrospray ionization mass spectrometry (MS) [<xref rid="B103-antibiotics-09-00325" ref-type="bibr">103</xref>,<xref rid="B104-antibiotics-09-00325" ref-type="bibr">104</xref>,<xref rid="B105-antibiotics-09-00325" ref-type="bibr">105</xref>,<xref rid="B106-antibiotics-09-00325" ref-type="bibr">106</xref>,<xref rid="B107-antibiotics-09-00325" ref-type="bibr">107</xref>,<xref rid="B108-antibiotics-09-00325" ref-type="bibr">108</xref>,<xref rid="B109-antibiotics-09-00325" ref-type="bibr">109</xref>,<xref rid="B110-antibiotics-09-00325" ref-type="bibr">110</xref>,<xref rid="B111-antibiotics-09-00325" ref-type="bibr">111</xref>,<xref rid="B112-antibiotics-09-00325" ref-type="bibr">112</xref>,<xref rid="B113-antibiotics-09-00325" ref-type="bibr">113</xref>,<xref rid="B114-antibiotics-09-00325" ref-type="bibr">114</xref>,<xref rid="B115-antibiotics-09-00325" ref-type="bibr">115</xref>,<xref rid="B116-antibiotics-09-00325" ref-type="bibr">116</xref>,<xref rid="B117-antibiotics-09-00325" ref-type="bibr">117</xref>,<xref rid="B118-antibiotics-09-00325" ref-type="bibr">118</xref>,<xref rid="B119-antibiotics-09-00325" ref-type="bibr">119</xref>,<xref rid="B120-antibiotics-09-00325" ref-type="bibr">120</xref>,<xref rid="B121-antibiotics-09-00325" ref-type="bibr">121</xref>,<xref rid="B122-antibiotics-09-00325" ref-type="bibr">122</xref>,<xref rid="B123-antibiotics-09-00325" ref-type="bibr">123</xref>,<xref rid="B124-antibiotics-09-00325" ref-type="bibr">124</xref>,<xref rid="B125-antibiotics-09-00325" ref-type="bibr">125</xref>,<xref rid="B126-antibiotics-09-00325" ref-type="bibr">126</xref>,<xref rid="B127-antibiotics-09-00325" ref-type="bibr">127</xref>,<xref rid="B128-antibiotics-09-00325" ref-type="bibr">128</xref>]. Most of the terpenes reported are known and their multiple chiral centers were assigned according to the literature. When chirality is not reported, terpenes were tested as racemic form (see <xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>) [<xref rid="B103-antibiotics-09-00325" ref-type="bibr">103</xref>,<xref rid="B107-antibiotics-09-00325" ref-type="bibr">107</xref>,<xref rid="B126-antibiotics-09-00325" ref-type="bibr">126</xref>,<xref rid="B129-antibiotics-09-00325" ref-type="bibr">129</xref>]. In some studies, the authors investigated the extract chemical composition by Gas Chromatography-mass spectrometry (GC/MS) [<xref rid="B129-antibiotics-09-00325" ref-type="bibr">129</xref>]. The chemical structure of the most representative terpenes examined in this review is shown in <xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>.</p><sec id="sec4dot1-antibiotics-09-00325"><title>4.1. Monoterpenes</title><p>Monoterpenes are the main constituents of essential oils and they are responsible of the flavor and aroma of plant from which they are extracted. They are formed by the dimerization of isoprene units and, based on the arrangement of their carbon skeleton, they are grouped into acyclic and cyclic structures [<xref rid="B132-antibiotics-09-00325" ref-type="bibr">132</xref>]. It is also useful to classify monoterpenes in line with their different chemical functionalities, including alcohol (such as linalool and geraniol), aldehyde (such as citral and citronellal), phenol (such as thymol and carvacrol), ketone (such as carvone and camphor), ether (such as eucalyptol) and hydrocarbon (such as cymene, pinene, limonene, and phellandrene) groups [<xref rid="B92-antibiotics-09-00325" ref-type="bibr">92</xref>]. It has been long recognized that monoterpenes possess antimicrobial activity. Griffin et al. investigated the relationships between the structure/molecular properties and the antimicrobial activity of terpenes. They found that hydrogen bonding parameters are associated with their biological activity, in all cases [<xref rid="B133-antibiotics-09-00325" ref-type="bibr">133</xref>]. Several oxygenate monoterpenes such as carvacrol, thymol, menthol, and geraniol exerted antimicrobial activity against several Gram(+) and Gram(&#x02212;) bacteria [<xref rid="B134-antibiotics-09-00325" ref-type="bibr">134</xref>]. In particular, geraniol (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>1</bold>), an acyclic monoterpene featuring alcoholic functionalization, has been extensively studied for its promising antimicrobial activities against MDR strains. Lorenzi et al. reported the ability of the essential oil, obtained from <italic>Helichrysum italicum</italic>, to significantly reduce the resistance of three pathogenic MDR Gram(&#x02212;) bacteria to chloramphenicol [<xref rid="B130-antibiotics-09-00325" ref-type="bibr">130</xref>]. The authors demonstrated the ability of the <italic>H. italicum</italic> essential oil to reduce chloramphenicol resistance of an <italic>Enterobacter aerogenes</italic> strain EAEP289 that over-expresses its AcrAB efflux pump, supporting their hypothesis regarding a potential efflux pump inhibitor (EPI) as a mechanism of antimicrobial activity. Further investigations confirmed that the essential oil derived from <italic>H. italicum</italic> contains one or more chemical constituents with EPI activity. Accordingly, chloramphenicol susceptibility testing was performed in the presence of several components of the most active fraction from the essential oil and, among them, geraniol resulted to be the most potent compound in reducing chloramphenicol minimum growth inhibitory concentration (MIC) up to 16-fold for the EAEP289 strain [<xref rid="B130-antibiotics-09-00325" ref-type="bibr">130</xref>]. In addition, geraniol completely reversed the chloramphenicol resistance in combination with the well-studied EPI, phenylalanine arginine &#x003b2;-naphthylamide (PA&#x003b2;N) control. Interestingly, the efficiency of geraniol in reducing drug resistance was also observed towards &#x003b2;-lactams and the fluoroquinolone norfloxacin highlighting that geraniol modulates antibiotic resistance in Gram(&#x02212;) bacteria by targeting efflux pumps mechanisms [<xref rid="B130-antibiotics-09-00325" ref-type="bibr">130</xref>]. Recently, Sayout et al. evaluated the antibacterial activity and the chemical composition of the essential oils from two species of the genus Lavandula: <italic>L. tenuisecta</italic> Coss.exBall and <italic>Lavandula pedunculata</italic> subsp.atlantica (BRAUN-BLANQ) [<xref rid="B129-antibiotics-09-00325" ref-type="bibr">129</xref>,<xref rid="B135-antibiotics-09-00325" ref-type="bibr">135</xref>]. Essential oils from both species showed antibacterial activity against several microorganisms leading to an increased interest for Lavandula genus in the treatment of bacterial infections caused by MDR strains. The two species are rich of oxygenated monoterpenes and the major constituents are camphor, fenchone and 1,8-cineole. The authors investigated the relationship between terpenoid constituents and antibacterial activity in order to identify the compound(s) that are responsible for the antibacterial activity of <italic>Lavandula atlantica</italic> essential oil. Among them, one of the major constituents, camphor (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>2</bold>), a bicyclic monoterpene ketone, exhibited antimicrobial activity against all the tested strains. Several other oxygenated monoterpenes isolated from <italic>Lavandula atlantica</italic> essential oil showed a strong antimicrobial activity against most of the studied strains. Among them, linalool (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>3</bold>), an acyclic monoterpene alcohol, with MIC values ranging from 1.44 &#x003bc;g/mL to 3.83 &#x003bc;g/mL; terpinen-4-ol (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>4</bold>), a cyclic monoterpene alcohol, with MIC values ranging from 0.78 &#x003bc;g/mL to 3.13-6.25 &#x003bc;g/mL; borneol (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>5</bold>), a bicyclic monoterpene alcohol, with MIC values ranging from 0.47 &#x003bc;g/mL to 3.75 &#x003bc;g/mL; and fenchone (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>6</bold>), a bicyclic monoterpene ketone, with MIC values ranging from 1.06 &#x003bc;g/mL to 4.25 &#x003bc;g/mL [<xref rid="B129-antibiotics-09-00325" ref-type="bibr">129</xref>,<xref rid="B135-antibiotics-09-00325" ref-type="bibr">135</xref>].</p></sec><sec id="sec4dot2-antibiotics-09-00325"><title>4.2. Sesquiterpenes</title><p>Sesquiterpenes are composed of three isoprene units and they are widely studied for their biological activities. Farnesol is a compound of 15 carbon atoms and can be considered the precursor of acyclic sesquiterpenes. This sesquiterpene, has shown a significant antimicrobial activity against several bacteria, including <italic>Staphylococcus aureus</italic> and <italic>S. epidermidis</italic>, with the ability to inhibit biofilm formation of <italic>Streptococcus</italic> spp. [<xref rid="B134-antibiotics-09-00325" ref-type="bibr">134</xref>]. Furthermore, it was found to potentiate the activity of &#x003b2;-lactam antibiotics against antibiotic-resistant bacteria [<xref rid="B136-antibiotics-09-00325" ref-type="bibr">136</xref>]. Recently, Kim et al. reported that two synthetic derivatives of farnesol (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compounds <bold>7</bold> and <bold>8</bold>) had an antimicrobial activity against three different methicillin-resistant <italic>S. aureus</italic> (MRSA) with MICs of 512 &#x003bc;g/mL and 256&#x02013;512 &#x003bc;g/mL for compounds <bold>8</bold> and <bold>7</bold>, respectively). In addition, they displayed an enhancer effect of &#x003b2;-lactam antibiotics. For instance, when used in combination with oxacillin against resistant strains, farnesol and their derivatives were able to reduce the oxacillin MIC of up to 128-fold. A lower, but still significant potentiating activity was also observed in combination with ampicillin [<xref rid="B127-antibiotics-09-00325" ref-type="bibr">127</xref>]. Moreover, by cyclization reactions a wide variety of monocyclic, bicyclic and tricyclic compounds can be formed [<xref rid="B132-antibiotics-09-00325" ref-type="bibr">132</xref>]. Lee et al. investigated the relationship between the sesquiterpene lactone structure and the antimicrobial activity. The authors demonstrated that the activity depends on the presence of a beta unsubstituted cyclopentenone ring moiety and how its saturation dramatically reduced activity [<xref rid="B137-antibiotics-09-00325" ref-type="bibr">137</xref>]. Several compounds belonging to the largest class of sesquiterpene lactones, the pseudo-guaianolides were also identified [<xref rid="B138-antibiotics-09-00325" ref-type="bibr">138</xref>]. Among them, Arnicolide D and Arnicolide C (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compounds <bold>9</bold> and <bold>10</bold>), isolated from <italic>Centipeda minima</italic>, a medicinal plants of Nepal, showed activity against both MRSA and methicillin sensitive <italic>S. aureus</italic> (MSSA) with MIC values of 300 &#x003bc;g/mL <italic>versus</italic> MRSA, and 75 &#x003bc;g/mL and 38 &#x003bc;g/mL <italic>versus</italic> MSSA, respectively [<xref rid="B103-antibiotics-09-00325" ref-type="bibr">103</xref>]. Furthermore, a related guaianolide 5 (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>11</bold>), isolated from <italic>Artemisia gilvescens</italic> manifested an excellent potential against a clinical strain of MRSA with a MIC value of 1.95 &#x003bc;g/mL [<xref rid="B104-antibiotics-09-00325" ref-type="bibr">104</xref>]. Ord&#x000f3;nez et al. studied the antimicrobial activity of two sesquiterpene lactones, belonging to the guainolide group, isolated from <italic>Gynoxys verrucosa</italic>, against six clinical isolates of <italic>S. aureus</italic> and <italic>S. epidermidis</italic> with different drug-resistance profiles. The sesquiterpene dehydroleucodine (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>12</bold>) exhibited antimicrobial activity against all staphylococcal isolates, including four methicillin-resistant strains with a minimum concentration inhibiting 50% bacterial growth (IC<sub>50</sub>) between 49 and 195 &#x003bc;g/mL. Interestingly, the antimicrobial activity of dehydroleucodine and other structurally related sesquiterpene lactones, such as Arnicolide C, against MRSA and MSSA strains, suggested that the presence of a carbonyl moiety in the opposite side of the cycloheptane ring acts as a secondary hydrogen binding point and that the methylene group in the lactone ring significantly affects antimicrobial activity [<xref rid="B105-antibiotics-09-00325" ref-type="bibr">105</xref>]. Among the phenolic sesquiterpenes, Xanthorrizol (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>13</bold>) from <italic>Cinnamomum iners</italic>, displayed significant antibacterial activity against MRSA with a MIC of 25 &#x003bc;g/mL [<xref rid="B106-antibiotics-09-00325" ref-type="bibr">106</xref>]. Goncalves et al. inquired into the antibacterial effect of a wide range of antibiotics, such as tetracycline, erythromycin, penicillin, and vancomycin, when combined with nine sesquiterpenic compounds, e.g., hydrocarbons and alcohols, on two clinically relevant <italic>S. aureus</italic> and <italic>Escherichia coli</italic> strains with well-defined resistance-sensitive profiles. Several combinations of antibiotic-sesquiterpenic compounds increased the antibacterial activity of the antibiotics against <italic>S. aureus</italic>. For <italic>E. coli</italic>, an antagonistic effect was observed. Moreover, this study paved the way for the evaluation of sesquiterpenes as possible antibiotic enhancer against MRSA [<xref rid="B139-antibiotics-09-00325" ref-type="bibr">139</xref>].</p></sec><sec id="sec4dot3-antibiotics-09-00325"><title>4.3. Diterpenes</title><p>Diterpenes consist of a chemically diverse group of compounds, all with a C20 carbon skeleton based on four isoprene units. They can be classified as linear, bicyclic, tricyclic, tetracyclic, pentacyclic or macrocyclic diterpenes depending on their skeletal core. A great number of diterpenes showed significant antimicrobial activity against MDR bacteria, and/or the ability to enhance the effectiveness of antibiotics when evaluated in combination with them against resistant strains [<xref rid="B90-antibiotics-09-00325" ref-type="bibr">90</xref>,<xref rid="B134-antibiotics-09-00325" ref-type="bibr">134</xref>,<xref rid="B140-antibiotics-09-00325" ref-type="bibr">140</xref>]. Labdane-type bicyclic diterpenes, featuring a decalin system and a six-member ring which may be open or closed with an oxygen atom, proved an interesting antimicrobial activity against MDR strains [<xref rid="B102-antibiotics-09-00325" ref-type="bibr">102</xref>]. Six new labdane-type diterpenes, isolated from the Malaysian species of <italic>Vitex vestita</italic> were tested for the first time against a panel of 46 Gram(+) bacterial strains, both sensitive or resistant to conventional antibiotics. Interestingly, vitexolide A (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>14</bold>) resulted the most active compound with MICs ranging from 2 to 32 &#x003bc;g/mL against all tested microorganisms and a MIC of 4 &#x003bc;g/mL against the human MDR <italic>S. aureus</italic> strain CRBIP 21.21. Acumenolide (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>15</bold>) indicated an anti-<italic>Bacillus</italic> activity (MIC of 16 &#x003bc;g/mL) while 12-epivitexolide A (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>16</bold>), the C12 epimer of vitexolide A, and acuminolide, showed moderate antibacterial activity against a panel of <italic>S. aureus</italic> strains with MIC values of 16 &#x003bc;g/mL. The structure-activity relationship analysis underlined that the presence of the &#x003b3;- hydroxybutenolide moiety along with a C12 hydroxylation are essential for the antimicrobial activity [<xref rid="B107-antibiotics-09-00325" ref-type="bibr">107</xref>]. Interestingly, another bicyclic diterpene with labdane-type scaffold, the 8(17),12E,14-labdatrien-6,19-olide (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>17</bold>), featuring a five-member lactone ring and three unsaturations, was isolated from <italic>Salvia leriifolia</italic> and showed a significant antimicrobial activity against a clinical MRSA strain with a MIC of 213 &#x000b5;M [<xref rid="B108-antibiotics-09-00325" ref-type="bibr">108</xref>]. A structurally related diterpene, 8(17),11(Z),13(E)-trien-15,19-dioic acid (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>18</bold>), isolated from <italic>Caesalpinia decapetala</italic> displayed a moderate antibacterial activity against a MRSA strain with a IC<sub>50</sub> of 5.99 &#x000b5;g/mL [<xref rid="B109-antibiotics-09-00325" ref-type="bibr">109</xref>]. Recently, Siddique et al. examined the antibacterial activity of a labdane diterpene, the (E)-8(17),12-labdadiene-15,16-dial (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>19</bold>) from <italic>Zingiber montanum</italic>, against a panel of clinical isolates of MDR <italic>S. aureus</italic> and MRSA and found out a potent activity with MICs ranging from 46 to 93 &#x000b5;g/mL. In addition, the authors pointed out that the unsaturations (exomethylene C-8 and olefine C-12) and the two aldehyde groups at C-16 and C-17 on the diterpenoid&#x02019;s carbon skeleton could account for the significant activity against MRSA strains [<xref rid="B110-antibiotics-09-00325" ref-type="bibr">110</xref>]. Gupta et al. reported the antimicrobial activity of a clerodane diterpene, 16&#x003b1;-hydroxycleroda-3, 13 (14)-<italic>Z</italic>-dien-15, 16-olide (CD) (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>20</bold>), isolated from leaves of <italic>Polyathia longifolia</italic>, against seven clinical MRSA isolates with MICs in the range of 15.625&#x02013;31.25 &#x003bc;g/mL (15.625 &#x003bc;g/mL against reference strain SA-96) [<xref rid="B128-antibiotics-09-00325" ref-type="bibr">128</xref>]. The authors also investigated the synergistic interactions and the resistance-modifying potential of CD in combination with fluoroquinolones against these strains and its efflux pump inhibitory potential [<xref rid="B141-antibiotics-09-00325" ref-type="bibr">141</xref>]. This diterpenoid enhanced the efficacy of norfloxacin, ciprofloxacin and ofloxacin against MRSA clinical isolates reducing up to 16-fold the MIC of norfloxacin against the MRSA clinical isolate ST2071. Furthermore, the results of time-kill kinetics revealed that CD in combination with norfloxacin at their &#x000bd;MIC significantly reduced the viability of bacterial cells while flow cytometric analysis and spectrofluorometric assay clearly indicated that CD diterpene inhibited an MDR efflux pump [<xref rid="B141-antibiotics-09-00325" ref-type="bibr">141</xref>]. The abietane-type is a class of tricyclic diterpenoid widespread in several botanical families. The aromatic abietanes are the largest group of naturally occurring abietanes. They are characterized by an aromatic C ring and a different degree of oxygenation at several positions. Generally, aromatic abietanes are not functionalized on the A-ring carbons. Most of them presents a different degree of oxidation in their B- and C-ring carbons [<xref rid="B142-antibiotics-09-00325" ref-type="bibr">142</xref>]. Gaspar-Marques C. et al., investigated the antibacterial effect of several natural abietanes isolated from <italic>Plectranthus grandidentatus</italic> and <italic>P. hereroensis</italic> against MRSA and vancomycin-resistant <italic>Enterococcus faecalis</italic> (VRE). Diterpenes coleon U, 7&#x003b1;-acetoxy-6&#x003b2;-hydroxyroyleanone and horminone (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>21</bold>, <bold>22</bold> and <bold>23</bold>) were the most active, with a remarkable activity against MRSA strains (MICs ranging from 0.98 &#x000b5;g/mL to 15.63 &#x000b5;g/mL) and a more moderate activity against VRE strains (MIC values from 15.63 and 31.25 &#x000b5;g/mL) [<xref rid="B111-antibiotics-09-00325" ref-type="bibr">111</xref>]. Among the other abietanes tested, diterpenes 7&#x003b1;,12-dihydroxy-17(15-16)abeo-abieta-8,12,16-triene-11,14-dione (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>24</bold>) and 16-acetoxy-7&#x003b1;,12-dihydroxy-8,12-abietadiene-11,14-dione (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>25</bold>) showed a weaker activity, with MICs comprised between 15.63 &#x000b5;g/mL and 62.50 &#x000b5;g/mL. The authors suggested that 12-hydroxy-p-benzoquinone moiety in ring C together with an oxidized B ring at the C-6 and C-7 positions are essential for antimicrobial activity against MRSA and VRE. Furthermore, the most promising compound, coleon U, consists of the more oxygenated and dehydrogenated chromophoric system through rings B and C. Moreover, the presence of the 6&#x003b2;-hydroxyl and 7&#x003b1;-acetoxy groups, as in 7&#x003b1;-acetoxy-6&#x003b2;-hydroxyroyleanone, or the oxidation at C7 position, as in horminone and abietanes 24 and 25, preserved a good antimicrobial activity [<xref rid="B111-antibiotics-09-00325" ref-type="bibr">111</xref>]. Recently, Jurkaninov&#x000e0; S. and co-workers evaluated the anti-MRSA activity of abietane diterpenes from <italic>Coleus blumei</italic> Benth. Sincoetsin C (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>26</bold>) was the most potent compound with a MIC of 128 &#x000b5;g/mL against the MRSA strain CCM 4750 whereas the abietane glucosides did not show a valuable growth inhibition of MRSA, suggesting that the glycosylation of the hydroxyl group on the abietane skeleton suppresses the anti-MRSA activity [<xref rid="B112-antibiotics-09-00325" ref-type="bibr">112</xref>]. Notably, Porto et al. studied the structure-antimicrobial activity relationships of pimarane-type diterpenes against MDRs, increasing the diversity of chemical structures by microbial transformation. Five tricyclic diterpene derivatives of the ent-8(14), 15-pimaradiene (PD), isolated from <italic>Viguiera arenaria</italic>, were obtained by fungal transformation in <italic>Aspergillus ochraceus</italic>. This allowed to introduce a reactive center into the poorly functionalized PD skeleton which was then tested against eight clinically isolated MDR bacteria. Interestingly, the diterpene derivative ent-8 (14), 15-pimaradien-3&#x003b2;-ol (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>27</bold>) was much more effective than its biosynthetic precursor, with promising MIC values (lower than 10.0 &#x003bc;g/mL) against a large variety of microbial pathogens. The time-kill curve experiments were carried out on MDR strain of <italic>S. aureus</italic> and showed that this compound was endowed with bactericidal action at all the evaluated concentrations (8.0, 16.0 and 24.0 &#x000b5;g/mL) within 24 h of incubation. Additionally, it was tested in combination with vancomycin at the minimal bactericidal concentration. Time-kill curve profile of resulting combination denoted that the number of viable microorganisms was drastically reduced within the first six hours. Furthermore, by comparing structural features of the tested compounds with biological data, the authors established that the antimicrobial activity of pimarane-type diterpenes was ruled by structural factors other than the hydrogen-bond-donor (HDB) Urz&#x000fa;a hypothesis suggesting that the structural requirements responsible for an efficient antibacterial activity include a lipophilic structure, capable of insertion into the cell membrane and one hydrophilic group (HBD) that interacts with the phosphorylated headgroups of membrane phospholipids [<xref rid="B113-antibiotics-09-00325" ref-type="bibr">113</xref>,<xref rid="B143-antibiotics-09-00325" ref-type="bibr">143</xref>]. In 2009, Stavri and co-workers analyzed the antimicrobial activity of three new diterpenes, isolated from <italic>Plectranthus ernstii</italic>, against a panel of MRSA. Among them, the pimarane diterpene rel-15(&#x003b6;),16-epoxy-7R- hydroxypimar-8,14-ene (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>28</bold>), exhibited moderate antistaphylococcal activity against MDR strains with a MIC of 32 &#x000b5;g/mL, whereas rel-15(&#x003b6;),16-epoxy-7-oxopimar-8,14-ene and 1R,11S-dihydroxy-8R,13R-epoxylabd-14-ene (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>29</bold> and <bold>30</bold>) showed a weaker activity. Surprisingly, a simple structural difference between the two pimarane diterpenes from 7-hydroxy to 7-oxo in the pimarane compound resulted in a loss of antistaphylococcal activity, presumably due to an increased lipophilicity and poorer uptake of the compound [<xref rid="B114-antibiotics-09-00325" ref-type="bibr">114</xref>]. Among the pimarane-type diterpenes, Smith et al. reported the antimicrobial activity of isopimaric acid (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>31</bold>), from <italic>Pinus nigra</italic>, against strains with MDR efflux pumps and epidemic MRSA with MIC from 32 &#x003bc;g/mL to 64 &#x003bc;g/mL [<xref rid="B115-antibiotics-09-00325" ref-type="bibr">115</xref>]. The authors also evaluated the activity of isopimaric acid in combination with tetracycline, norfloxacin and erythromycin or ofloxacin against the corresponding strains. However, no reduction of MIC was obtained for any of the antibiotics. Interestingly, isopimaric acid tested in combination with the efflux pump inhibitor reserpine (20 &#x003bc;g/mL) against two resistant strains, significantly increased the MIC for this compound. The authors postulated that isopimaric acid is not a substrate for these efflux pumps, but it is also possible that an antagonistic interaction with reserpine may render the antibiotics inactive. A molecular modeling study, performed by Zloh et al., reported the possible formation of complexes between MDR inhibitors and the substrates of efflux pumps. This would facilitate the entry of MDR inhibitors into the cell, following by complex dissociation, to allow the drug displaying its effect [<xref rid="B144-antibiotics-09-00325" ref-type="bibr">144</xref>]. Based on this finding, it is possible that the complex formation is due to strong interactions, with a very slow rate of dissociation. This would lower the concentration of the free drug thus decreasing its anti-bacterial activity. Further investigations by Smith et al. supported this hypothesis highlighting a possible complex formation between diterpenes and reserpine responsible for a reduction in activity [<xref rid="B115-antibiotics-09-00325" ref-type="bibr">115</xref>]. Recently, Soares A.C. and co-workers analyzed the antibacterial activity of two natural diterpenes against a set of seven clinically isolated MRD bacteria, including three <italic>S. aureus</italic> strains [<xref rid="B116-antibiotics-09-00325" ref-type="bibr">116</xref>]. The two diterpenes, the tetracyclic <italic>ent</italic>-kaurenoic acid and the tricyclic ent-pimaradienoic acid (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>32</bold> and <bold>33</bold>), featuring a different basic skeleton, were isolated from <italic>Mikania glomerata</italic> and <italic>Viguiera arenaria</italic>, respectively, and selected for this study according to the Urz&#x000fa;a hypothesis. The biological assays gave MIC values lower than 13 &#x000b5;g/mL, supporting the HBD Urz&#x000fa;a hypothesis. In order to perform structure-activity relationships studies the authors developed several semi-synthetic derivatives from both natural diterpenes. The hydrogenated product derivative of 33 (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>34</bold>), resulted to be even more efficient as an antimicrobial agent against MRSA and <italic>S. capitis</italic> with a MIC of 6.25 &#x003bc;g/mL [<xref rid="B116-antibiotics-09-00325" ref-type="bibr">116</xref>]. Furthermore, Barbosa et al. reported the potent antibacterial activity of the <italic>ent</italic>-kaurenoic acid isolated from <italic>C. reticulata</italic> oleoresin against MRSA (IC<sub>50</sub> 3.4 &#x000b5;g/mL) [<xref rid="B117-antibiotics-09-00325" ref-type="bibr">117</xref>]. Interestingly, a docking-based virtual screening of an <italic>in-house</italic> library of natural products within the catalytic site of ArnT, the enzyme responsible for colistin resistance mediated by lipid A aminoarabinosylation in <italic>Pseudomonas aeruginosa</italic>, led to the identification of the ent-beyer-15-en-18-O-oxalate (BBN149, <xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>35</bold>), as promising inhibitor of ArnT [<xref rid="B118-antibiotics-09-00325" ref-type="bibr">118</xref>]. This natural tetracyclic diterpene, featuring the <italic>ent</italic>-beyerene scaffold, was isolated from <italic>Fabiana densa</italic> var. <italic>ramulosa</italic>. The compound demonstrated to act as potent colistin adjuvant, potentiating its antibacterial activity up to 16-fold against colistin-resistant <italic>P. aeruginosa</italic> and <italic>K. pneumoniae</italic> isolates. The compound showed no activity against colistin-susceptible strains and no relevant toxicity towards human cells. The binding mode of BBN149 within the catalytic site of ArnT was evaluated by molecular docking simulations and identified two main binding poses. In both poses, the oxalyl group nicely overlaps with the crystallographic phosphate moiety and establishes H-bond interaction with the Lys85 residue, which was shown to be important for ArnT activity. Notably, this new insight made this diterpene a promising candidate for lead optimization of colistin resistance inhibitors with improved activity and/or pharmacological properties. Furthermore, natural analogs of the initial hit compound were isolated, and several semisynthetic analogs were designed and synthesized to afford structure-activity relationships (SAR). Currently, these data are covered by a patent [<xref rid="B145-antibiotics-09-00325" ref-type="bibr">145</xref>].</p></sec><sec id="sec4dot4-antibiotics-09-00325"><title>4.4. Triterpenes</title><p>Triterpenes are composed by a carbon skeleton of six isoprene units and the main groups are represented by tetracyclic and pentacyclic structures. Pentacyclic triterpenes are all based on a 30-carbons skeleton comprising five six-membered rings (such as ursanes and lanostanes) or four six-membered rings and one five-membered ring (such as lupanes and hopanes). Interestingly, several pentacyclic triterpenes have been described for their antimicrobial activity [<xref rid="B146-antibiotics-09-00325" ref-type="bibr">146</xref>,<xref rid="B147-antibiotics-09-00325" ref-type="bibr">147</xref>]. Chung et al. reported the antimicrobial activity of &#x003b1;-amyrin, betulinic acid and betulinaldehyde (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>36</bold>, <bold>37</bold> and <bold>38</bold>) against clinical isolates of MRSA and MSSA with MICs ranging from 64 to 512 &#x003bc;g/mL [<xref rid="B119-antibiotics-09-00325" ref-type="bibr">119</xref>]. These pentacyclic triterpenes featured five six-membered rings, in the case of &#x003b1;-amyrin, or four six-membered rings and one five-membered ring, for betulinic acid and betulinaldehyde. Noteworthy, although their MICs were higher than those of the commonly used antibiotics vancomycin and methicillin, the combinations of these drugs with such pentacyclic triterpenes reduced the MIC to a range of 0.05 to 50%. Interestingly, the authors also demonstrated the potential synergistic activity of the standard antibiotics with these diterpenes on MRSA and MSSA [<xref rid="B119-antibiotics-09-00325" ref-type="bibr">119</xref>]. Horiuchi et al. identify oleanolic acid, a pentacyclic triterpenoid related to betulinic acid, as the compound responsible for the antimicrobial activity of the <italic>Salvia officinalis</italic> (Sage) leaves extract against VRE. This pentacyclic triterpene (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>39</bold>), an olean-12-en-28-oic acid substituted by a beta-hydroxy group at position 3, displayed a good activity against VRE and MRSA strains with MIC values of 8 &#x000b5;g/mL and 16 &#x000b5;g/mL, respectively. To get insight into structure-antimicrobial activity relationships, the authors tested structural related triterpenes and, among them, ursolic acid (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>40</bold>), the C19 epimer of oleanolic acid. It showed a higher antimicrobial activity against both VRE and MRSA strains with MIC values of 4 &#x000b5;g/mL and 8 &#x000b5;g/mL, respectively [<xref rid="B120-antibiotics-09-00325" ref-type="bibr">120</xref>]. Furthermore, ursolic acid, isolated from <italic>Eucalyptus tereticornis</italic>, did not exhibit antibacterial activity against the nalidixic acid-sensitive (NASEC) and nalidixic acid-resistant (NAREC) strains of <italic>E. coli</italic>, but in combination with nalidixic acid, this pentacyclic triterpene reduced the MIC of drug by two-fold (MIC of nalidixic acid alone was 6.25 &#x000b5;g/mL on NASEC and 100 &#x000b5;g/mL against NAREC). Based on these results, several semisynthetic derivatives of ursolic acid were developed and tested to evaluate their drug resistance reversal potential. Among them, the butyl and isopropyl ester of ursolic acid (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>41</bold> and <bold>42</bold>) reduced the MIC of nalidixic acid by 8-fold against NAREC and by 4- to 8-fold against NASEC [<xref rid="B121-antibiotics-09-00325" ref-type="bibr">121</xref>]. Furthermore, in a study reported by Wang et al. on the antibacterial and synergistic activity of pentacyclic triterpenes isolated from <italic>Alstonia scholaris</italic>, ursolic acid showed a good antimicrobial activity against Gram(+) pathogens including a MRSA strain, with a MIC value of 64 &#x000b5;g/mL and a synergistic effect with ampicillin and tetracycline against this strain [<xref rid="B122-antibiotics-09-00325" ref-type="bibr">122</xref>]. A preliminary screening of a 350 compound proprietary in-house library containing marketed drugs and natural compounds to identify small molecules able to potentiate the antibacterial activity of some antibiotics against MRSA strains, led to the selection of 18&#x003b2;-glycyrrhetinic acid (18&#x003b2;-GA, <xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>43</bold>), as the most active compound against <italic>S. aureus</italic> ATCC6538. It is a pentacyclic triterpene featuring five six-membered rings and found in nature together with its 18&#x003b1;-epimer (18&#x003b1;-GA) as aglycons of glycyrrhizin in <italic>Glycyrrhiza glabra</italic>. The authors discovered a synergistic effect of 18&#x003b2;-GA with several antibiotics against the MRSA strain LUH14616. Notably, this triterpene also potentiated the activity of tobramycin (16&#x02013;32-fold), amikacin (8-fold) and polymyxin B (32&#x02013;64-fold) against LUH21416, indicating 18&#x003b2;-GA as a good antibiotic enhancer against MRSA [<xref rid="B131-antibiotics-09-00325" ref-type="bibr">131</xref>]. Recently, the lupane triterpene 3&#x003b2;,6&#x003b2;,16&#x003b2;-trihydroxylup-20(29)-ene (CLF1, <xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>44</bold>), isolated from <italic>Combretum leprosum</italic> Mart. leaves, showed antibacterial action with clinical relevance against 10 MDR strains with MIC &#x02265; 4&#x02009;&#x000b5;g/mL and, more interestingly, synergistic effects were observed in combination with the antibiotic amikacin, reducing the MIC value from 100 &#x000b5;g/mL to 80 &#x000b5;g/mL. In addition, this pentacyclic triterpene increased antimicrobial activity against MDR <italic>E. coli</italic> when associated with the antibiotics gentamicin and amikacin lowering MIC values from 20 &#x000b5;g/mL to 15 &#x000b5;g/mL and from 100 &#x000b5;g/mL to 60 &#x000b5;g/mL [<xref rid="B123-antibiotics-09-00325" ref-type="bibr">123</xref>]. Noteworthy, the triterpenes with cycloartane skeleton were active against the antibiotic resistant clinical isolates [<xref rid="B148-antibiotics-09-00325" ref-type="bibr">148</xref>]. These triterpenes have a unique pentacyclic structure characterized by cyclopropyl methylene group on the carbon skeleton. In a study reported by Gutierrez-Lugo et al., three cycloartane-type triterpenes i.e., 16R-hydroxymollic, 15R-hydroxymollic and 7&#x003b2;,16&#x003b2;-dihydroxy-1,23-dideoxyjessic acids (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compounds <bold>45</bold>, <bold>46</bold> and <bold>47</bold>), isolated from the aerial parts of <italic>Acalypha communis</italic>, exhibited moderate antimicrobial activity against VRE with MIC values of 8 &#x003bc;g/mL, 32 &#x003bc;g/mL and 8 &#x003bc;g/mL, respectively. In addition, 45 also displayed moderate activity against MRSA (MIC 64 &#x000b5;g/mL) [<xref rid="B124-antibiotics-09-00325" ref-type="bibr">124</xref>]. Furthermore, Wang et al. evaluated the antimicrobial activity of new five cycloartane-type triterpenes, isolated from <italic>Acacia grandifolia</italic>, against two MRSA strains. These compounds consisted in three new 29-nor-cycloart triterpenes aphagrandinoids A&#x02013;C, and a new natural product, aphagrandinoid D (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>48</bold>), along with a structurally related known one (20R)-3&#x003b2;-hydroxy-24,25,26,27-tetranor-5&#x003b1;-cycloartan-23,21-olid. Among these compounds, the last triterpene, belonging to the 3&#x003b2;-cycloartanol series, showed the strongest antibacterial activity against MRSA strains (MIC values of 1.57 &#x003bc;g/mL <italic>versus</italic> 25 or 50 &#x003bc;g/mL), despite a slightly weaker antimicrobial potency compared to the commercial drug vancomycin (MIC of 0.78 &#x003bc;g/mL) [<xref rid="B122-antibiotics-09-00325" ref-type="bibr">122</xref>]. Several triterpenes with tetracyclic structures were also found to be active against MDR strains. In line with this, Mosa et al. evaluated the antibacterial activity of two triterpenes i.e., 3&#x003b2;-hydroxylanosta-9, 24-dien-21-oic acid and methyl-3&#x003b2;-hydroxylanosta9,24-dienoate (<xref rid="antibiotics-09-00325-t003" ref-type="table">Table 3</xref>, compound <bold>49</bold> and <bold>50</bold>), isolated from <italic>Protorhus longifolia</italic>, against a panel of antibiotic resistant Gram(+) and Gram(&#x02212;) bacteria. The triterpenes had an antibacterial activity comparable to that of conventional antibiotics against resistant strains of <italic>S. aureus</italic> [<xref rid="B126-antibiotics-09-00325" ref-type="bibr">126</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec5-antibiotics-09-00325"><title>5. Conclusions</title><p>Despite the discovery of antibiotics that has saved millions of lives from microbial infections, the latter continue to be a serious threat to public health due to the appearance of resistant strains. New molecules with antimicrobial activities are therefore urgently needed. Plant-derived terpenes represent an interesting class of molecules with a multitude of activities that make them of reference for drug-discovery as proven by the numerous clinical trials and drugs on the market ( <xref rid="antibiotics-09-00325-t001" ref-type="table">Table 1</xref>; <xref rid="antibiotics-09-00325-t002" ref-type="table">Table 2</xref>). Terpenes also possess antimicrobial activity and, in recent years, the studies we have reported have shown their ability to act also against antibiotic-resistant strains. This class of compounds therefore has all the potential for the development of new antimicrobials, especially in this post-antibiotic era in which we are living.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge networking contribution by the COST Action CM1407 &#x0201c;Challenging Organic Syntheses Inspired by Nature&#x02212;From Natural Products Chemistry to Drug Discovery&#x0201d;.</p></ack><notes><title>Author Contributions</title><p>F.G. conceptualized the review. F.C., M.R.L., B.C. and D.Q. wrote the manuscript. C.D.P. and S.C. contributed in writing the manuscript and designed figures and tables. M.L.M. and B.B. critically revised the manuscript. All authors have red and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was supported from PON (Piano Operativo Nazionale) Grant ARS01_00432 PROGEMA, &#x0201c;Processi Green per l&#x02019;Estrazione di Principi Attivi e la Depurazione di Matrici di Scarto e Non&#x0201d;, 03/2018&#x02212;09/2020 and PRIN 2017-&#x0201c;Targeting Hedgehog pathway: Virtual screening identification and sustainable synthesis of novel Smo and Gli inhibitors and their pharmacological drug delivery strategies for improved therapeutic effects in tumors&#x0201d; by the Italian Ministry of Education, University and Research (MIUR) and Sapienza University of Rome. This work was also supported by MIUR&#x02212; Dipartimenti di Eccellenza&#x02212; L. 232/2016 and Sapienza University of Rome (Project RM11816436113D8A).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-antibiotics-09-00325"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>G.</given-names></name></person-group><article-title>The discovery of penicillin&#x02014;new insights after more than 75 years of clinical use</article-title><source>Emerg. Infect. Dis. J.</source><year>2017</year><volume>23</volume><fpage>849</fpage></element-citation></ref><ref id="B2-antibiotics-09-00325"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro da Cunha</surname><given-names>B.</given-names></name><name><surname>Fonseca</surname><given-names>L.P.</given-names></name><name><surname>Calado</surname><given-names>C.R.C.</given-names></name></person-group><article-title>Antibiotic discovery: Where have we come from, where do we go?</article-title><source>Antibiotics</source><year>2019</year><volume>8</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics8020045</pub-id><?supplied-pmid 31022923?><pub-id pub-id-type="pmid">31022923</pub-id></element-citation></ref><ref id="B3-antibiotics-09-00325"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>L.L.</given-names></name></person-group><article-title>Challenges of antibacterial discovery</article-title><source>Clin. Microbiol. Rev.</source><year>2011</year><volume>24</volume><fpage>71</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1128/CMR.00030-10</pub-id><?supplied-pmid 21233508?><pub-id pub-id-type="pmid">21233508</pub-id></element-citation></ref><ref id="B4-antibiotics-09-00325"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>K.</given-names></name></person-group><article-title>Antibiotics: From prehistory to the present day</article-title><source>J Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>572</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv484</pub-id><pub-id pub-id-type="pmid">26851273</pub-id></element-citation></ref><ref id="B5-antibiotics-09-00325"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zappia</surname><given-names>G.</given-names></name><name><surname>Ingallina</surname><given-names>C.</given-names></name><name><surname>Ghirga</surname><given-names>F.</given-names></name><name><surname>Botta</surname><given-names>B.</given-names></name></person-group><article-title>Oxazolidin-2-ones: Antibacterial activity and chemistry</article-title><source>Antimicrobials: New and Old Molecules in the Fight against Multi-Resistant Bacteria</source><person-group person-group-type="editor"><name><surname>Marinelli</surname><given-names>F.</given-names></name><name><surname>Genilloud</surname><given-names>O.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>2014</year><fpage>247</fpage><lpage>266</lpage></element-citation></ref><ref id="B6-antibiotics-09-00325"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rather</surname><given-names>I.A.</given-names></name><name><surname>Kim</surname><given-names>B.C.</given-names></name><name><surname>Bajpai</surname><given-names>V.K.</given-names></name><name><surname>Park</surname><given-names>Y.H.</given-names></name></person-group><article-title>Self-medication and antibiotic resistance: Crisis, current challenges, and prevention</article-title><source>Saudi. J. Biol. Sci.</source><year>2017</year><volume>24</volume><fpage>808</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/j.sjbs.2017.01.004</pub-id><pub-id pub-id-type="pmid">28490950</pub-id></element-citation></ref><ref id="B7-antibiotics-09-00325"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodds</surname><given-names>D.R.</given-names></name></person-group><article-title>Antibiotic resistance: A current epilogue</article-title><source>Biochem. Pharmacol.</source><year>2017</year><volume>134</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2016.12.005</pub-id><pub-id pub-id-type="pmid">27956111</pub-id></element-citation></ref><ref id="B8-antibiotics-09-00325"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>M.L.</given-names></name><name><surname>Mueller</surname><given-names>L.V.</given-names></name><name><surname>Polyakov</surname><given-names>M.</given-names></name><name><surname>Weinstock</surname><given-names>S.F.</given-names></name></person-group><article-title>Where have all the antibiotic patents gone?</article-title><source>Nat. Biotechnol.</source><year>2006</year><volume>24</volume><fpage>1529</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1038/nbt1206-1529</pub-id><pub-id pub-id-type="pmid">17160057</pub-id></element-citation></ref><ref id="B9-antibiotics-09-00325"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>C.N.</given-names></name></person-group><article-title>Low hanging fruit in infectious disease drug development</article-title><source>Curr. Opin. Microbiol.</source><year>2008</year><volume>11</volume><fpage>434</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2008.09.009</pub-id><pub-id pub-id-type="pmid">18822387</pub-id></element-citation></ref><ref id="B10-antibiotics-09-00325"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Projan</surname><given-names>S.J.</given-names></name></person-group><article-title>Why is big pharma getting out of antibacterial drug discovery?</article-title><source>Curr. Opin. Microbiol.</source><year>2003</year><volume>6</volume><fpage>427</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2003.08.003</pub-id><pub-id pub-id-type="pmid">14572532</pub-id></element-citation></ref><ref id="B11-antibiotics-09-00325"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Projan</surname><given-names>S.J.</given-names></name><name><surname>Shlaes</surname><given-names>D.M.</given-names></name></person-group><article-title>Antibacterial drug discovery: Is it all downhill from here?</article-title><source>Clin. Microbiol. Infect.</source><year>2004</year><volume>10</volume><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1111/j.1465-0691.2004.1006.x</pub-id></element-citation></ref><ref id="B12-antibiotics-09-00325"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spellberg</surname><given-names>B.</given-names></name><name><surname>Powers</surname><given-names>J.H.</given-names></name><name><surname>Brass</surname><given-names>E.P.</given-names></name><name><surname>Miller</surname><given-names>L.G.</given-names></name><name><surname>Edwards</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Trends in antimicrobial drug development: Implications for the future</article-title><source>Clin. Infect. Dis.</source><year>2004</year><volume>38</volume><fpage>1279</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1086/420937</pub-id><?supplied-pmid 15127341?><pub-id pub-id-type="pmid">15127341</pub-id></element-citation></ref><ref id="B13-antibiotics-09-00325"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassini</surname><given-names>A.</given-names></name><name><surname>Hogberg</surname><given-names>L.D.</given-names></name><name><surname>Plachouras</surname><given-names>D.</given-names></name><name><surname>Quattrocchi</surname><given-names>A.</given-names></name><name><surname>Hoxha</surname><given-names>A.</given-names></name><name><surname>Simonsen</surname><given-names>G.S.</given-names></name><name><surname>Colomb-Cotinat</surname><given-names>M.</given-names></name><name><surname>Kretzschmar</surname><given-names>M.E.</given-names></name><name><surname>Devleesschauwer</surname><given-names>B.</given-names></name><name><surname>Cecchini</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the eu and the european economic area in 2015: A population-level modelling analysis</article-title><source>Lancet Infect. Dis</source><year>2019</year><volume>19</volume><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30605-4</pub-id><pub-id pub-id-type="pmid">30409683</pub-id></element-citation></ref><ref id="B14-antibiotics-09-00325"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renwick</surname><given-names>M.J.</given-names></name><name><surname>Brogan</surname><given-names>D.M.</given-names></name><name><surname>Mossialos</surname><given-names>E.</given-names></name></person-group><article-title>A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics</article-title><source>J. Antibiot. (Tokyo)</source><year>2016</year><volume>69</volume><fpage>73</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/ja.2015.98</pub-id><?supplied-pmid 26464014?><pub-id pub-id-type="pmid">26464014</pub-id></element-citation></ref><ref id="B15-antibiotics-09-00325"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>S.Y.</given-names></name><name><surname>Tatsumura</surname><given-names>Y.</given-names></name></person-group><article-title>Alexander fleming (1881-1955): Discoverer of penicillin</article-title><source>Singap. Med. J.</source><year>2015</year><volume>56</volume><fpage>366</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.11622/smedj.2015105</pub-id><?supplied-pmid 26243971?><pub-id pub-id-type="pmid">26243971</pub-id></element-citation></ref><ref id="B16-antibiotics-09-00325"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reygaert</surname><given-names>W.C.</given-names></name></person-group><article-title>An overview of the antimicrobial resistance mechanisms of bacteria</article-title><source>AIMS Microbiol.</source><year>2018</year><volume>4</volume><fpage>482</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.3934/microbiol.2018.3.482</pub-id><?supplied-pmid 31294229?><pub-id pub-id-type="pmid">31294229</pub-id></element-citation></ref><ref id="B17-antibiotics-09-00325"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>T.K.</given-names></name><name><surname>Knabel</surname><given-names>S.J.</given-names></name><name><surname>Kwan</surname><given-names>B.W.</given-names></name></person-group><article-title>Bacterial persister cell formation and dormancy</article-title><source>Appl. Environ. Microbiol.</source><year>2013</year><volume>79</volume><fpage>7116</fpage><lpage>7121</lpage><pub-id pub-id-type="doi">10.1128/AEM.02636-13</pub-id><pub-id pub-id-type="pmid">24038684</pub-id></element-citation></ref><ref id="B18-antibiotics-09-00325"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keren</surname><given-names>I.</given-names></name><name><surname>Kaldalu</surname><given-names>N.</given-names></name><name><surname>Spoering</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Lewis</surname><given-names>K.</given-names></name></person-group><article-title>Persister cells and tolerance to antimicrobials</article-title><source>FEMS Microbiol. Lett.</source><year>2004</year><volume>230</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/S0378-1097(03)00856-5</pub-id><pub-id pub-id-type="pmid">14734160</pub-id></element-citation></ref><ref id="B19-antibiotics-09-00325"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>J.L.</given-names></name></person-group><article-title>General principles of antibiotic resistance in bacteria</article-title><source>Drug Discov. Today Technol.</source><year>2014</year><volume>11</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2014.02.001</pub-id><pub-id pub-id-type="pmid">24847651</pub-id></element-citation></ref><ref id="B20-antibiotics-09-00325"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arzanlou</surname><given-names>M.</given-names></name><name><surname>Chai</surname><given-names>W.C.</given-names></name><name><surname>Venter</surname><given-names>H.</given-names></name></person-group><article-title>Intrinsic, adaptive and acquired antimicrobial resistance in gram-negative bacteria</article-title><source>Essays Biochem.</source><year>2017</year><volume>61</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">28258229</pub-id></element-citation></ref><ref id="B21-antibiotics-09-00325"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>G.</given-names></name><name><surname>Wright</surname><given-names>G.D.</given-names></name></person-group><article-title>Intrinsic antibiotic resistance: Mechanisms, origins, challenges and solutions</article-title><source>Int. J. Med. Microbiol.</source><year>2013</year><volume>303</volume><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2013.02.009</pub-id><pub-id pub-id-type="pmid">23499305</pub-id></element-citation></ref><ref id="B22-antibiotics-09-00325"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>J.M.</given-names></name><name><surname>Webber</surname><given-names>M.A.</given-names></name><name><surname>Baylay</surname><given-names>A.J.</given-names></name><name><surname>Ogbolu</surname><given-names>D.O.</given-names></name><name><surname>Piddock</surname><given-names>L.J.</given-names></name></person-group><article-title>Molecular mechanisms of antibiotic resistance</article-title><source>Nat. Rev. Microbiol.</source><year>2015</year><volume>13</volume><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3380</pub-id><?supplied-pmid 25435309?><pub-id pub-id-type="pmid">25435309</pub-id></element-citation></ref><ref id="B23-antibiotics-09-00325"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coculescu</surname><given-names>B.I.</given-names></name></person-group><article-title>Antimicrobial resistance induced by genetic changes</article-title><source>J. Med. Life.</source><year>2009</year><volume>2</volume><fpage>114</fpage><lpage>123</lpage><?supplied-pmid 20108530?><pub-id pub-id-type="pmid">20108530</pub-id></element-citation></ref><ref id="B24-antibiotics-09-00325"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>J.</given-names></name><name><surname>Davies</surname><given-names>D.</given-names></name></person-group><article-title>Origins and evolution of antibiotic resistance</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2010</year><volume>74</volume><fpage>417</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00016-10</pub-id><?supplied-pmid 20805405?><pub-id pub-id-type="pmid">20805405</pub-id></element-citation></ref><ref id="B25-antibiotics-09-00325"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>R.F.</given-names></name><name><surname>Sa-Correia</surname><given-names>I.</given-names></name><name><surname>Valvano</surname><given-names>M.A.</given-names></name></person-group><article-title>Lipopolysaccharide modification in gram-negative bacteria during chronic infection</article-title><source>FEMS Microbiol. Rev.</source><year>2016</year><volume>40</volume><fpage>480</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1093/femsre/fuw007</pub-id><?supplied-pmid 27075488?><pub-id pub-id-type="pmid">27075488</pub-id></element-citation></ref><ref id="B26-antibiotics-09-00325"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>J.M.</given-names></name><name><surname>Richmond</surname><given-names>G.E.</given-names></name><name><surname>Piddock</surname><given-names>L.J.</given-names></name></person-group><article-title>Multidrug efflux pumps in gram-negative bacteria and their role in antibiotic resistance</article-title><source>Future Microbiol.</source><year>2014</year><volume>9</volume><fpage>1165</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.2217/fmb.14.66</pub-id><pub-id pub-id-type="pmid">25405886</pub-id></element-citation></ref><ref id="B27-antibiotics-09-00325"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>U.</given-names></name><name><surname>Lee</surname><given-names>C.R.</given-names></name></person-group><article-title>Distinct roles of outer membrane porins in antibiotic resistance and membrane integrity in <italic>Escherichia coli</italic></article-title><source>Front Microbiol.</source><year>2019</year><volume>10</volume><fpage>953</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.00953</pub-id><pub-id pub-id-type="pmid">31114568</pub-id></element-citation></ref><ref id="B28-antibiotics-09-00325"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Sato</surname><given-names>K.</given-names></name><name><surname>Okuma</surname><given-names>K.</given-names></name><name><surname>Tenover</surname><given-names>F.C.</given-names></name><name><surname>Mamizuka</surname><given-names>E.M.</given-names></name><name><surname>Gemmell</surname><given-names>C.G.</given-names></name><name><surname>Kim</surname><given-names>M.N.</given-names></name><name><surname>Ploy</surname><given-names>M.C.</given-names></name><name><surname>El-Solh</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus</article-title><source>J. Clin. Microbiol.</source><year>2003</year><volume>41</volume><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">12517819</pub-id></element-citation></ref><ref id="B29-antibiotics-09-00325"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>A.B.</given-names></name><name><surname>Vinuela-Prieto</surname><given-names>J.M.</given-names></name><name><surname>Lopez-Gonzalez</surname><given-names>L.</given-names></name><name><surname>Candel</surname><given-names>F.J.</given-names></name></person-group><article-title>Correlation between resistance mechanisms in <italic>Staphylococcus aureus</italic> and cell wall and septum thickening</article-title><source>Infect. Drug Resist</source><year>2017</year><volume>10</volume><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.2147/IDR.S146748</pub-id><pub-id pub-id-type="pmid">29089777</pub-id></element-citation></ref><ref id="B30-antibiotics-09-00325"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bebear</surname><given-names>C.</given-names></name><name><surname>Pereyre</surname><given-names>S.</given-names></name><name><surname>Peuchant</surname><given-names>O.</given-names></name></person-group><article-title><italic>Mycoplasma pneumoniae</italic>: Susceptibility and resistance to antibiotics</article-title><source>Future Microbiol.</source><year>2011</year><volume>6</volume><fpage>423</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.2217/fmb.11.18</pub-id><pub-id pub-id-type="pmid">21526943</pub-id></element-citation></ref><ref id="B31-antibiotics-09-00325"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tooke</surname><given-names>C.L.</given-names></name><name><surname>Hinchliffe</surname><given-names>P.</given-names></name><name><surname>Bragginton</surname><given-names>E.C.</given-names></name><name><surname>Colenso</surname><given-names>C.K.</given-names></name><name><surname>Hirvonen</surname><given-names>V.H.A.</given-names></name><name><surname>Takebayashi</surname><given-names>Y.</given-names></name><name><surname>Spencer</surname><given-names>J.</given-names></name></person-group><article-title>Beta-lactamases and beta-lactamase inhibitors in the 21st century</article-title><source>J. Mol. Biol.</source><year>2019</year><volume>431</volume><fpage>3472</fpage><lpage>3500</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.04.002</pub-id><pub-id pub-id-type="pmid">30959050</pub-id></element-citation></ref><ref id="B32-antibiotics-09-00325"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casciaro</surname><given-names>B.</given-names></name><name><surname>Loffredo</surname><given-names>M.R.</given-names></name><name><surname>Luca</surname><given-names>V.</given-names></name><name><surname>Verrusio</surname><given-names>W.</given-names></name><name><surname>Cacciafesta</surname><given-names>M.</given-names></name><name><surname>Mangoni</surname><given-names>M.L.</given-names></name></person-group><article-title>Esculentin-1a derived antipseudomonal peptides: Limited induction of resistance and synergy with aztreonam</article-title><source>Protein Pept. Lett.</source><year>2018</year><volume>25</volume><fpage>1155</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.2174/0929866525666181101104649</pub-id><?supplied-pmid 30381056?><pub-id pub-id-type="pmid">30381056</pub-id></element-citation></ref><ref id="B33-antibiotics-09-00325"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>J.H.</given-names></name><name><surname>Cha</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>Y.G.</given-names></name></person-group><article-title>Crystal structures of penicillin-binding protein d2 from <italic>Listeria monocytogenes</italic> and structural basis for antibiotic specificity</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><fpage>e00796-18</fpage><pub-id pub-id-type="doi">10.1128/AAC.00796-18</pub-id><?supplied-pmid 30082290?><pub-id pub-id-type="pmid">30082290</pub-id></element-citation></ref><ref id="B34-antibiotics-09-00325"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Rao</surname><given-names>X.</given-names></name></person-group><article-title>Vancomycin resistant <italic>Staphylococcus aureus</italic> infections: A review of case updating and clinical features</article-title><source>J. Adv. Res.</source><year>2020</year><volume>21</volume><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.jare.2019.10.005</pub-id><?supplied-pmid 32071785?><pub-id pub-id-type="pmid">32071785</pub-id></element-citation></ref><ref id="B35-antibiotics-09-00325"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassanzadeh</surname><given-names>S.</given-names></name><name><surname>Ganjloo</surname><given-names>S.</given-names></name><name><surname>Pourmand</surname><given-names>M.R.</given-names></name><name><surname>Mashhadi</surname><given-names>R.</given-names></name><name><surname>Ghazvini</surname><given-names>K.</given-names></name></person-group><article-title>Epidemiology of efflux pumps genes mediating resistance among <italic>Staphylococcus aureus</italic>; a systematic review</article-title><source>Microb. Pathog.</source><year>2020</year><volume>139</volume><fpage>103850</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2019.103850</pub-id><?supplied-pmid 31706002?><pub-id pub-id-type="pmid">31706002</pub-id></element-citation></ref><ref id="B36-antibiotics-09-00325"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghajavand</surname><given-names>H.</given-names></name><name><surname>Kargarpour Kamakoli</surname><given-names>M.</given-names></name><name><surname>Khanipour</surname><given-names>S.</given-names></name><name><surname>Pourazar Dizaji</surname><given-names>S.</given-names></name><name><surname>Masoumi</surname><given-names>M.</given-names></name><name><surname>Rahimi Jamnani</surname><given-names>F.</given-names></name><name><surname>Fateh</surname><given-names>A.</given-names></name><name><surname>Yaseri</surname><given-names>M.</given-names></name><name><surname>Siadat</surname><given-names>S.D.</given-names></name><name><surname>Vaziri</surname><given-names>F.</given-names></name></person-group><article-title>Scrutinizing the drug resistance mechanism of multi- and extensively-drug resistant <italic>Mycobacterium tuberculosis</italic>: Mutations versus efflux pumps</article-title><source>Antimicrob. Resist Infect. Control</source><year>2019</year><volume>8</volume><fpage>70</fpage><pub-id pub-id-type="doi">10.1186/s13756-019-0516-4</pub-id><?supplied-pmid 31073401?><pub-id pub-id-type="pmid">31073401</pub-id></element-citation></ref><ref id="B37-antibiotics-09-00325"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miryala</surname><given-names>S.K.</given-names></name><name><surname>Anbarasu</surname><given-names>A.</given-names></name><name><surname>Ramaiah</surname><given-names>S.</given-names></name></person-group><article-title>Systems biology studies in <italic>Pseudomonas aeruginosa</italic> PA01 to understand their role in biofilm formation and multidrug efflux pumps</article-title><source>Microb. Pathog.</source><year>2019</year><volume>136</volume><fpage>103668</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2019.103668</pub-id><pub-id pub-id-type="pmid">31419460</pub-id></element-citation></ref><ref id="B38-antibiotics-09-00325"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casciaro</surname><given-names>B.</given-names></name><name><surname>Dutta</surname><given-names>D.</given-names></name><name><surname>Loffredo</surname><given-names>M.R.</given-names></name><name><surname>Marcheggiani</surname><given-names>S.</given-names></name><name><surname>McDermott</surname><given-names>A.M.</given-names></name><name><surname>Willcox</surname><given-names>M.D.</given-names></name><name><surname>Mangoni</surname><given-names>M.L.</given-names></name></person-group><article-title>Esculentin-1a derived peptides kill <italic>Pseudomonas aeruginosa</italic> biofilm on soft contact lenses and retain antibacterial activity upon immobilization to the lens surface</article-title><source>Pept. Sci.</source><year>2018</year><volume>110</volume><fpage>e23074</fpage><pub-id pub-id-type="doi">10.1002/bip.23074</pub-id></element-citation></ref><ref id="B39-antibiotics-09-00325"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crouzet</surname><given-names>M.</given-names></name><name><surname>Claverol</surname><given-names>S.</given-names></name><name><surname>Lomenech</surname><given-names>A.M.</given-names></name><name><surname>Le Senechal</surname><given-names>C.</given-names></name><name><surname>Costaglioli</surname><given-names>P.</given-names></name><name><surname>Barthe</surname><given-names>C.</given-names></name><name><surname>Garbay</surname><given-names>B.</given-names></name><name><surname>Bonneu</surname><given-names>M.</given-names></name><name><surname>Vilain</surname><given-names>S.</given-names></name></person-group><article-title><italic>Pseudomonas aeruginosa</italic> cells attached to a surface display a typical proteome early as 20 min of incubation</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0180341</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0180341</pub-id><pub-id pub-id-type="pmid">28678862</pub-id></element-citation></ref><ref id="B40-antibiotics-09-00325"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>W.F.</given-names></name><name><surname>Silva</surname><given-names>P.M.S.</given-names></name><name><surname>Silva</surname><given-names>R.C.S.</given-names></name><name><surname>Silva</surname><given-names>G.M.M.</given-names></name><name><surname>Machado</surname><given-names>G.</given-names></name><name><surname>Coelho</surname><given-names>L.</given-names></name><name><surname>Correia</surname><given-names>M.T.S.</given-names></name></person-group><article-title><italic>Staphylococcus aureus</italic> and <italic>Staphylococcus epidermidis</italic> infections on implants</article-title><source>J. Hosp. Infect.</source><year>2018</year><volume>98</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2017.11.008</pub-id><pub-id pub-id-type="pmid">29175074</pub-id></element-citation></ref><ref id="B41-antibiotics-09-00325"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casciaro</surname><given-names>B.</given-names></name><name><surname>Moros</surname><given-names>M.</given-names></name><name><surname>Rivera-Fernandez</surname><given-names>S.</given-names></name><name><surname>Bellelli</surname><given-names>A.</given-names></name><name><surname>de la Fuente</surname><given-names>J.M.</given-names></name><name><surname>Mangoni</surname><given-names>M.L.</given-names></name></person-group><article-title>Gold-nanoparticles coated with the antimicrobial peptide esculentin-1a(1-21)NH<sub>2</sub> as a reliable strategy for antipseudomonal drugs</article-title><source>Acta. Biomater.</source><year>2017</year><volume>47</volume><fpage>170</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2016.09.041</pub-id><pub-id pub-id-type="pmid">27693686</pub-id></element-citation></ref><ref id="B42-antibiotics-09-00325"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>d&#x02019;Angelo</surname><given-names>I.</given-names></name><name><surname>Casciaro</surname><given-names>B.</given-names></name><name><surname>Miro</surname><given-names>A.</given-names></name><name><surname>Quaglia</surname><given-names>F.</given-names></name><name><surname>Mangoni</surname><given-names>M.L.</given-names></name><name><surname>Ungaro</surname><given-names>F.</given-names></name></person-group><article-title>Overcoming barriers in <italic>Pseudomonas aeruginosa</italic> lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide</article-title><source>Coll. Surf. B Biointerfaces</source><year>2015</year><volume>135</volume><fpage>717</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2015.08.027</pub-id><?supplied-pmid 26340361?><pub-id pub-id-type="pmid">26340361</pub-id></element-citation></ref><ref id="B43-antibiotics-09-00325"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casciaro</surname><given-names>B.</given-names></name><name><surname>d&#x02019;Angelo</surname><given-names>I.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Loffredo</surname><given-names>M.R.</given-names></name><name><surname>Conte</surname><given-names>G.</given-names></name><name><surname>Cappiello</surname><given-names>F.</given-names></name><name><surname>Quaglia</surname><given-names>F.</given-names></name><name><surname>Di</surname><given-names>Y.P.</given-names></name><name><surname>Ungaro</surname><given-names>F.</given-names></name><name><surname>Mangoni</surname><given-names>M.L.</given-names></name></person-group><article-title>Poly(lactide- co-glycolide) nanoparticles for prolonged therapeutic efficacy of esculentin-1a-derived antimicrobial peptides against Pseudomonas aeruginosa lung infection: In vitro and in vivo studies</article-title><source>Biomacromolecules</source><year>2019</year><volume>20</volume><fpage>1876</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.8b01829</pub-id><?supplied-pmid 31013061?><pub-id pub-id-type="pmid">31013061</pub-id></element-citation></ref><ref id="B44-antibiotics-09-00325"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>Y.</given-names></name><name><surname>Soto</surname><given-names>S.M.</given-names></name></person-group><article-title>The usefulness of microalgae compounds for preventing biofilm infections</article-title><source>Antibiotics</source><year>2019</year><volume>9</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics9010009</pub-id><?supplied-pmid 31878164?><pub-id pub-id-type="pmid">31878164</pub-id></element-citation></ref><ref id="B45-antibiotics-09-00325"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casciaro</surname><given-names>B.</given-names></name><name><surname>Lin</surname><given-names>Q.</given-names></name><name><surname>Afonin</surname><given-names>S.</given-names></name><name><surname>Loffredo</surname><given-names>M.R.</given-names></name><name><surname>de Turris</surname><given-names>V.</given-names></name><name><surname>Middel</surname><given-names>V.</given-names></name><name><surname>Ulrich</surname><given-names>A.S.</given-names></name><name><surname>Di</surname><given-names>Y.P.</given-names></name><name><surname>Mangoni</surname><given-names>M.L.</given-names></name></person-group><article-title>Inhibition of <italic>Pseudomonas aeruginosa</italic> biofilm formation and expression of virulence genes by selective epimerization in the peptide esculentin-1a(1-21)NH<sub>2</sub></article-title><source>FEBS J.</source><year>2019</year><volume>286</volume><fpage>3874</fpage><lpage>3891</lpage><pub-id pub-id-type="doi">10.1111/febs.14940</pub-id><?supplied-pmid 31144441?><pub-id pub-id-type="pmid">31144441</pub-id></element-citation></ref><ref id="B46-antibiotics-09-00325"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>M.</given-names></name><name><surname>Heinrich</surname><given-names>M.</given-names></name><name><surname>Booker</surname><given-names>A.</given-names></name></person-group><article-title>Medicinal plant analysis: A historical and regional discussion of emergent complex techniques</article-title><source>Front Pharmacol.</source><year>2019</year><volume>10</volume><fpage>1480</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.01480</pub-id><pub-id pub-id-type="pmid">31998121</pub-id></element-citation></ref><ref id="B47-antibiotics-09-00325"><label>47.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sneader</surname><given-names>W.</given-names></name></person-group><article-title>The prehistoric period</article-title><source>Drug Discovery</source><publisher-name>John Wiley &#x00026; Sons</publisher-name><publisher-loc>Chichester, UK</publisher-loc><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2006</year><fpage>6</fpage><lpage>11</lpage></element-citation></ref><ref id="B48-antibiotics-09-00325"><label>48.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sneader</surname><given-names>W.</given-names></name></person-group><article-title>Pre-hellenic civilisations</article-title><source>Drug discovery</source><publisher-name>John Wiley &#x00026; Sons</publisher-name><publisher-loc>Chichester, UK</publisher-loc><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2006</year><fpage>12</fpage><lpage>17</lpage></element-citation></ref><ref id="B49-antibiotics-09-00325"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cragg</surname><given-names>G.M.</given-names></name><name><surname>Newman</surname><given-names>D.J.</given-names></name></person-group><article-title>Natural products: A continuing source of novel drug leads</article-title><source>Biochim. Biophys. Acta.</source><year>2013</year><volume>1830</volume><fpage>3670</fpage><lpage>3695</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2013.02.008</pub-id><pub-id pub-id-type="pmid">23428572</pub-id></element-citation></ref><ref id="B50-antibiotics-09-00325"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eigenschink</surname><given-names>M.</given-names></name><name><surname>Dearing</surname><given-names>L.</given-names></name><name><surname>Dablander</surname><given-names>T.E.</given-names></name><name><surname>Maier</surname><given-names>J.</given-names></name><name><surname>Sitte</surname><given-names>H.H.</given-names></name></person-group><article-title>A critical examination of the main premises of traditional chinese medicine</article-title><source>Wien. Klin. Wochenschr.</source><year>2020</year><volume>132</volume><fpage>260</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1007/s00508-020-01625-w</pub-id><pub-id pub-id-type="pmid">32198544</pub-id></element-citation></ref><ref id="B51-antibiotics-09-00325"><label>51.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sneader</surname><given-names>W.</given-names></name></person-group><source>Drug Discovery</source><publisher-name>John Wiley and Sons</publisher-name><publisher-loc>Chichester, UK</publisher-loc><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2006</year><fpage>18</fpage><lpage>23</lpage></element-citation></ref><ref id="B52-antibiotics-09-00325"><label>52.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sneader</surname><given-names>W.</given-names></name></person-group><article-title>Herbals</article-title><source>Drug Discovery</source><publisher-name>John Wiley and Sons</publisher-name><publisher-loc>Chichester, UK</publisher-loc><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2006</year><fpage>32</fpage><lpage>40</lpage></element-citation></ref><ref id="B53-antibiotics-09-00325"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calixto</surname><given-names>J.B.</given-names></name></person-group><article-title>The role of natural products in modern drug discovery</article-title><source>An. Acad. Bras. Cienc.</source><year>2019</year><volume>91</volume><fpage>e20190105</fpage><pub-id pub-id-type="doi">10.1590/0001-3765201920190105</pub-id><pub-id pub-id-type="pmid">31166478</pub-id></element-citation></ref><ref id="B54-antibiotics-09-00325"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palermo</surname><given-names>R.</given-names></name><name><surname>Ghirga</surname><given-names>F.</given-names></name><name><surname>Piccioni</surname><given-names>M.G.</given-names></name><name><surname>Bernardi</surname><given-names>F.</given-names></name><name><surname>Zhdanovskaya</surname><given-names>N.</given-names></name><name><surname>Infante</surname><given-names>P.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name></person-group><article-title>Natural products inspired modulators of cancer stem cells-specific signaling pathways notch and hedgehog</article-title><source>Curr. Pharm. Des.</source><year>2018</year><volume>24</volume><fpage>4251</fpage><lpage>4269</lpage><pub-id pub-id-type="doi">10.2174/1381612825666190111124822</pub-id><pub-id pub-id-type="pmid">30636589</pub-id></element-citation></ref><ref id="B55-antibiotics-09-00325"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>J.D.</given-names></name><name><surname>Tatonetti</surname><given-names>N.P.</given-names></name></person-group><article-title>Informatics and computational methods in natural product drug discovery: A review and perspectives</article-title><source>Front. Genet</source><year>2019</year><volume>10</volume><fpage>368</fpage><pub-id pub-id-type="doi">10.3389/fgene.2019.00368</pub-id><pub-id pub-id-type="pmid">31114606</pub-id></element-citation></ref><ref id="B56-antibiotics-09-00325"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>B.</given-names></name><name><surname>Wolfender</surname><given-names>J.-L.</given-names></name><name><surname>Dias</surname><given-names>D.A.</given-names></name></person-group><article-title>The pharmaceutical industry and natural products: Historical status and new trends</article-title><source>Phytochem. Rev.</source><year>2015</year><volume>14</volume><fpage>299</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1007/s11101-014-9367-z</pub-id></element-citation></ref><ref id="B57-antibiotics-09-00325"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucar</surname><given-names>F.</given-names></name><name><surname>Wube</surname><given-names>A.</given-names></name><name><surname>Schmid</surname><given-names>M.</given-names></name></person-group><article-title>Natural product isolation--how to get from biological material to pure compounds</article-title><source>Nat. Prod. Rep.</source><year>2013</year><volume>30</volume><fpage>525</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1039/c3np20106f</pub-id><?supplied-pmid 23396532?><pub-id pub-id-type="pmid">23396532</pub-id></element-citation></ref><ref id="B58-antibiotics-09-00325"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinghorn</surname><given-names>A.D.</given-names></name><name><surname>Pan</surname><given-names>L.</given-names></name><name><surname>Fletcher</surname><given-names>J.N.</given-names></name><name><surname>Chai</surname><given-names>H.</given-names></name></person-group><article-title>The relevance of higher plants in lead compound discovery programs</article-title><source>J. Nat. Prod.</source><year>2011</year><volume>74</volume><fpage>1539</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1021/np200391c</pub-id><?supplied-pmid 21650152?><pub-id pub-id-type="pmid">21650152</pub-id></element-citation></ref><ref id="B59-antibiotics-09-00325"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henrich</surname><given-names>C.J.</given-names></name><name><surname>Beutler</surname><given-names>J.A.</given-names></name></person-group><article-title>Matching the power of high throughput screening to the chemical diversity of natural products</article-title><source>Nat. Prod. Rep.</source><year>2013</year><volume>30</volume><fpage>1284</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1039/c3np70052f</pub-id><pub-id pub-id-type="pmid">23925671</pub-id></element-citation></ref><ref id="B60-antibiotics-09-00325"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coan</surname><given-names>K.E.</given-names></name><name><surname>Ottl</surname><given-names>J.</given-names></name><name><surname>Klumpp</surname><given-names>M.</given-names></name></person-group><article-title>Non-stoichiometric inhibition in biochemical high-throughput screening</article-title><source>Expert Opin. Drug Discov.</source><year>2011</year><volume>6</volume><fpage>405</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1517/17460441.2011.561309</pub-id><pub-id pub-id-type="pmid">22646018</pub-id></element-citation></ref><ref id="B61-antibiotics-09-00325"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>T.A.</given-names></name><name><surname>Sohn</surname><given-names>J.</given-names></name><name><surname>Inman</surname><given-names>W.D.</given-names></name><name><surname>Estee</surname><given-names>S.A.</given-names></name><name><surname>Loveridge</surname><given-names>S.T.</given-names></name><name><surname>Vervoort</surname><given-names>H.C.</given-names></name><name><surname>Tenney</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Ang</surname><given-names>K.K.</given-names></name><name><surname>Ratnam</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Natural product libraries to accelerate the high-throughput discovery of therapeutic leads</article-title><source>J. Nat. Prod.</source><year>2011</year><volume>74</volume><fpage>2545</fpage><lpage>2555</lpage><pub-id pub-id-type="doi">10.1021/np200673b</pub-id><pub-id pub-id-type="pmid">22129061</pub-id></element-citation></ref><ref id="B62-antibiotics-09-00325"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Ven</surname><given-names>W.</given-names></name><name><surname>Verbiest</surname><given-names>T.</given-names></name><name><surname>Koeckelberghs</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Vermorken</surname><given-names>A.</given-names></name></person-group><article-title>Polyphenols can inhibit furin in vitro as a result of the reactivity of their auto-oxidation products to proteins</article-title><source>Curr. Med. Chem.</source><year>2012</year><volume>20</volume><fpage>840</fpage><lpage>850</lpage></element-citation></ref><ref id="B63-antibiotics-09-00325"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balunas</surname><given-names>M.J.</given-names></name><name><surname>Su</surname><given-names>B.</given-names></name><name><surname>Landini</surname><given-names>S.</given-names></name><name><surname>Brueggemeier</surname><given-names>R.W.</given-names></name><name><surname>Kinghorn</surname><given-names>A.D.</given-names></name></person-group><article-title>Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay</article-title><source>J. Nat. Prod.</source><year>2006</year><volume>69</volume><fpage>700</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1021/np050513p</pub-id><pub-id pub-id-type="pmid">16643058</pub-id></element-citation></ref><ref id="B64-antibiotics-09-00325"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corson</surname><given-names>T.W.</given-names></name><name><surname>Crews</surname><given-names>C.M.</given-names></name></person-group><article-title>Molecular understanding and modern application of traditional medicines: Triumphs and trials</article-title><source>Cell</source><year>2007</year><volume>130</volume><fpage>769</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.08.021</pub-id><pub-id pub-id-type="pmid">17803898</pub-id></element-citation></ref><ref id="B65-antibiotics-09-00325"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>M.</given-names></name></person-group><article-title>Ethnopharmacology in the 21st century&#x02014;Grand challenges</article-title><source>Front Pharmacol.</source><year>2010</year><volume>1</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.3389/fphar.2010.00008</pub-id><pub-id pub-id-type="pmid">21713103</pub-id></element-citation></ref><ref id="B66-antibiotics-09-00325"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>M.</given-names></name><name><surname>Gibbons</surname><given-names>S.</given-names></name></person-group><article-title>Ethnopharmacology in drug discovery: An analysis of its role and potential contribution</article-title><source>J. Pharm. Pharmacol.</source><year>2001</year><volume>53</volume><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1211/0022357011775712</pub-id><?supplied-pmid 11341358?><pub-id pub-id-type="pmid">11341358</pub-id></element-citation></ref><ref id="B67-antibiotics-09-00325"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>G.D.</given-names></name></person-group><article-title>Unlocking the potential of natural products in drug discovery</article-title><source>Microb. Biotechnol.</source><year>2019</year><volume>12</volume><fpage>55</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1111/1751-7915.13351</pub-id><pub-id pub-id-type="pmid">30565871</pub-id></element-citation></ref><ref id="B68-antibiotics-09-00325"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linington</surname><given-names>R.G.</given-names></name><name><surname>Kubanek</surname><given-names>J.</given-names></name><name><surname>Luesch</surname><given-names>H.</given-names></name></person-group><article-title>New methods for isolation and structure determination of natural products</article-title><source>Nat. Prod. Rep.</source><year>2019</year><volume>36</volume><fpage>942</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1039/C9NP90023C</pub-id><pub-id pub-id-type="pmid">31250867</pub-id></element-citation></ref><ref id="B69-antibiotics-09-00325"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>B.A.P.</given-names></name><name><surname>Thornburg</surname><given-names>C.C.</given-names></name><name><surname>Henrich</surname><given-names>C.J.</given-names></name><name><surname>Grkovic</surname><given-names>T.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name></person-group><article-title>Creating and screening natural product libraries</article-title><source>Nat. Prod. Rep.</source><year>2020</year><pub-id pub-id-type="doi">10.1039/C9NP00068B</pub-id><?supplied-pmid 32186299?><pub-id pub-id-type="pmid">32186299</pub-id></element-citation></ref><ref id="B70-antibiotics-09-00325"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Infante</surname><given-names>P.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name><name><surname>Alfonsi</surname><given-names>R.</given-names></name><name><surname>Ghirga</surname><given-names>F.</given-names></name><name><surname>Aiello</surname><given-names>F.</given-names></name><name><surname>Toscano</surname><given-names>S.</given-names></name><name><surname>Ingallina</surname><given-names>C.</given-names></name><name><surname>Siler</surname><given-names>M.</given-names></name><name><surname>Cucchi</surname><given-names>D.</given-names></name><name><surname>Po</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Gli1/DNA interaction is a druggable target for hedgehog-dependent tumors</article-title><source>EMBO J.</source><year>2015</year><volume>34</volume><fpage>200</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.15252/embj.201489213</pub-id><?supplied-pmid 25476449?><pub-id pub-id-type="pmid">25476449</pub-id></element-citation></ref><ref id="B71-antibiotics-09-00325"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingallina</surname><given-names>C.</given-names></name><name><surname>Costa</surname><given-names>P.M.</given-names></name><name><surname>Ghirga</surname><given-names>F.</given-names></name><name><surname>Klippstein</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>J.T.</given-names></name><name><surname>Berardozzi</surname><given-names>S.</given-names></name><name><surname>Hodgins</surname><given-names>N.</given-names></name><name><surname>Infante</surname><given-names>P.</given-names></name><name><surname>Pollard</surname><given-names>S.M.</given-names></name><name><surname>Botta</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Polymeric glabrescione b nanocapsules for passive targeting of hedgehog-dependent tumor therapy</article-title><source>In Vitro Nanomed. (Lond.)</source><year>2017</year><volume>12</volume><fpage>711</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.2217/nnm-2016-0388</pub-id><?supplied-pmid 28322108?><pub-id pub-id-type="pmid">28322108</pub-id></element-citation></ref><ref id="B72-antibiotics-09-00325"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>M.</given-names></name><name><surname>Tottone</surname><given-names>L.</given-names></name><name><surname>Quaglio</surname><given-names>D.</given-names></name><name><surname>Zhdanovskaya</surname><given-names>N.</given-names></name><name><surname>Ingallina</surname><given-names>C.</given-names></name><name><surname>Fusto</surname><given-names>M.</given-names></name><name><surname>Ghirga</surname><given-names>F.</given-names></name><name><surname>Peruzzi</surname><given-names>G.</given-names></name><name><surname>Crestoni</surname><given-names>M.E.</given-names></name><name><surname>Simeoni</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Identification of a novel chalcone derivative that inhibits notch signaling in t-cell acute lymphoblastic leukemia</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>2213</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-02316-9</pub-id><pub-id pub-id-type="pmid">28526832</pub-id></element-citation></ref><ref id="B73-antibiotics-09-00325"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casciaro</surname><given-names>B.</given-names></name><name><surname>Calcaterra</surname><given-names>A.</given-names></name><name><surname>Cappiello</surname><given-names>F.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name><name><surname>Loffredo</surname><given-names>M.R.</given-names></name><name><surname>Ghirga</surname><given-names>F.</given-names></name><name><surname>Mangoni</surname><given-names>M.L.</given-names></name><name><surname>Botta</surname><given-names>B.</given-names></name><name><surname>Quaglio</surname><given-names>D.</given-names></name></person-group><article-title>Nigritanine as a new potential antimicrobial alkaloid for the treatment of <italic>Staphylococcus aureus</italic>-induced infections</article-title><source>Toxins</source><year>2019</year><volume>11</volume><elocation-id>511</elocation-id><pub-id pub-id-type="doi">10.3390/toxins11090511</pub-id></element-citation></ref><ref id="B74-antibiotics-09-00325"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cevatemre</surname><given-names>B.</given-names></name><name><surname>Botta</surname><given-names>B.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name><name><surname>Berardozzi</surname><given-names>S.</given-names></name><name><surname>Ingallina</surname><given-names>C.</given-names></name><name><surname>Ulukaya</surname><given-names>E.</given-names></name></person-group><article-title>The plant-derived triterpenoid tingenin b is a potent anticancer agent due to its cytotoxic activity on cancer stem cells of breast cancer in vitro</article-title><source>Chem. Biol. Interact.</source><year>2016</year><volume>260</volume><fpage>248</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2016.10.001</pub-id><?supplied-pmid 27720947?><pub-id pub-id-type="pmid">27720947</pub-id></element-citation></ref><ref id="B75-antibiotics-09-00325"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Circi</surname><given-names>S.</given-names></name><name><surname>Capitani</surname><given-names>D.</given-names></name><name><surname>Randazzo</surname><given-names>A.</given-names></name><name><surname>Ingallina</surname><given-names>C.</given-names></name><name><surname>Mannina</surname><given-names>L.</given-names></name><name><surname>Sobolev</surname><given-names>A.P.</given-names></name></person-group><article-title>Panel test and chemical analyses of commercial olive oils: A comparative study</article-title><source>Chem. Biol. Technol. Agric.</source><year>2017</year><volume>4</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/s40538-017-0101-0</pub-id></element-citation></ref><ref id="B76-antibiotics-09-00325"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berardozzi</surname><given-names>S.</given-names></name><name><surname>Bernardi</surname><given-names>F.</given-names></name><name><surname>Infante</surname><given-names>P.</given-names></name><name><surname>Ingallina</surname><given-names>C.</given-names></name><name><surname>Toscano</surname><given-names>S.</given-names></name><name><surname>De Paolis</surname><given-names>E.</given-names></name><name><surname>Alfonsi</surname><given-names>R.</given-names></name><name><surname>Caimano</surname><given-names>M.</given-names></name><name><surname>Botta</surname><given-names>B.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Synergistic inhibition of the hedgehog pathway by newly designed smo and gli antagonists bearing the isoflavone scaffold</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>156</volume><fpage>554</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.07.017</pub-id><?supplied-pmid 30025349?><pub-id pub-id-type="pmid">30025349</pub-id></element-citation></ref><ref id="B77-antibiotics-09-00325"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quaglio</surname><given-names>D.</given-names></name><name><surname>Zhdanovskaya</surname><given-names>N.</given-names></name><name><surname>Tobajas</surname><given-names>G.</given-names></name><name><surname>Cuartas</surname><given-names>V.</given-names></name><name><surname>Balducci</surname><given-names>S.</given-names></name><name><surname>Christodoulou</surname><given-names>M.S.</given-names></name><name><surname>Fabrizi</surname><given-names>G.</given-names></name><name><surname>Gargantilla</surname><given-names>M.</given-names></name><name><surname>Priego</surname><given-names>E.M.</given-names></name><name><surname>Carmona Pestana</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Chalcones and chalcone-mimetic derivatives as notch inhibitors in a model of t-cell acute lymphoblastic leukemia</article-title><source>ACS Med. Chem. Lett.</source><year>2019</year><volume>10</volume><fpage>639</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.8b00608</pub-id><?supplied-pmid 30996810?><pub-id pub-id-type="pmid">30996810</pub-id></element-citation></ref><ref id="B78-antibiotics-09-00325"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lospinoso Severini</surname><given-names>L.</given-names></name><name><surname>Quaglio</surname><given-names>D.</given-names></name><name><surname>Basili</surname><given-names>I.</given-names></name><name><surname>Ghirga</surname><given-names>F.</given-names></name><name><surname>Bufalieri</surname><given-names>F.</given-names></name><name><surname>Caimano</surname><given-names>M.</given-names></name><name><surname>Balducci</surname><given-names>S.</given-names></name><name><surname>Moretti</surname><given-names>M.</given-names></name><name><surname>Romeo</surname><given-names>I.</given-names></name><name><surname>Loricchio</surname><given-names>E.</given-names></name><etal/></person-group><article-title>A smo/gli multitarget hedgehog pathway inhibitor impairs tumor growth</article-title><source>Cancers</source><year>2019</year><volume>11</volume><elocation-id>1518</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11101518</pub-id><?supplied-pmid 31601026?><pub-id pub-id-type="pmid">31601026</pub-id></element-citation></ref><ref id="B79-antibiotics-09-00325"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mushtaq</surname><given-names>S.</given-names></name><name><surname>Abbasi</surname><given-names>B.H.</given-names></name><name><surname>Uzair</surname><given-names>B.</given-names></name><name><surname>Abbasi</surname><given-names>R.</given-names></name></person-group><article-title>Natural products as reservoirs of novel therapeutic agents</article-title><source>EXCLI J.</source><year>2018</year><volume>17</volume><fpage>420</fpage><lpage>451</lpage><?supplied-pmid 29805348?><pub-id pub-id-type="pmid">29805348</pub-id></element-citation></ref><ref id="B80-antibiotics-09-00325"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atanasov</surname><given-names>A.G.</given-names></name><name><surname>Waltenberger</surname><given-names>B.</given-names></name><name><surname>Pferschy-Wenzig</surname><given-names>E.M.</given-names></name><name><surname>Linder</surname><given-names>T.</given-names></name><name><surname>Wawrosch</surname><given-names>C.</given-names></name><name><surname>Uhrin</surname><given-names>P.</given-names></name><name><surname>Temml</surname><given-names>V.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Schwaiger</surname><given-names>S.</given-names></name><name><surname>Heiss</surname><given-names>E.H.</given-names></name><etal/></person-group><article-title>Discovery and resupply of pharmacologically active plant-derived natural products: A review</article-title><source>Biotechnol. Adv.</source><year>2015</year><volume>33</volume><fpage>1582</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2015.08.001</pub-id><?supplied-pmid 26281720?><pub-id pub-id-type="pmid">26281720</pub-id></element-citation></ref><ref id="B81-antibiotics-09-00325"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>D.J.</given-names></name><name><surname>Cragg</surname><given-names>G.M.</given-names></name></person-group><article-title>Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019</article-title><source>J. Nat. Prod.</source><year>2020</year><volume>83</volume><fpage>770</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b01285</pub-id><pub-id pub-id-type="pmid">32162523</pub-id></element-citation></ref><ref id="B82-antibiotics-09-00325"><label>82.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Osbourn</surname><given-names>A.E.</given-names></name><name><surname>Lanzotti</surname><given-names>V.</given-names></name></person-group><source>Plant-Derived Natural Products</source><publisher-name>Springer</publisher-name><publisher-loc>Dordrecht, The Netherlands</publisher-loc><year>2009</year><fpage>361</fpage><lpage>384</lpage></element-citation></ref><ref id="B83-antibiotics-09-00325"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramani</surname><given-names>R.</given-names></name><name><surname>Narayanasamy</surname><given-names>M.</given-names></name><name><surname>Feussner</surname><given-names>K.D.</given-names></name></person-group><article-title>Plant-derived antimicrobials to fight against multi-drug-resistant human pathogens</article-title><source>3 Biotech.</source><year>2017</year><volume>7</volume><fpage>172</fpage><pub-id pub-id-type="doi">10.1007/s13205-017-0848-9</pub-id></element-citation></ref><ref id="B84-antibiotics-09-00325"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>P.</given-names></name><name><surname>Jun</surname><given-names>X.</given-names></name><name><surname>Cheng</surname><given-names>P.</given-names></name></person-group><article-title>Pharmacological properties of geraniol&#x02014;A review</article-title><source>Planta Med.</source><year>2019</year><volume>85</volume><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1055/a-0750-6907</pub-id><pub-id pub-id-type="pmid">30308694</pub-id></element-citation></ref><ref id="B85-antibiotics-09-00325"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cragg</surname><given-names>G.</given-names></name><name><surname>Newman</surname><given-names>D.</given-names></name><name><surname>Kingston</surname><given-names>D.</given-names></name></person-group><article-title>Terrestrial plants as a source of novel pharmaceutical agents</article-title><source>Compr. Nat. Prod. II Chem. Biol.</source><year>2010</year><volume>2</volume><fpage>5</fpage><lpage>39</lpage></element-citation></ref><ref id="B86-antibiotics-09-00325"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieira</surname><given-names>A.J.</given-names></name><name><surname>Beserra</surname><given-names>F.P.</given-names></name><name><surname>Souza</surname><given-names>M.C.</given-names></name><name><surname>Totti</surname><given-names>B.M.</given-names></name><name><surname>Rozza</surname><given-names>A.L.</given-names></name></person-group><article-title>Limonene: Aroma of innovation in health and disease</article-title><source>Chem. Biol. Interact.</source><year>2018</year><volume>283</volume><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2018.02.007</pub-id><?supplied-pmid 29427589?><pub-id pub-id-type="pmid">29427589</pub-id></element-citation></ref><ref id="B87-antibiotics-09-00325"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>M.S.</given-names></name><name><surname>Robertson</surname><given-names>A.A.</given-names></name><name><surname>Cooper</surname><given-names>M.A.</given-names></name></person-group><article-title>Natural product and natural product derived drugs in clinical trials</article-title><source>Nat. Prod. Rep.</source><year>2014</year><volume>31</volume><fpage>1612</fpage><lpage>1661</lpage><pub-id pub-id-type="doi">10.1039/C4NP00064A</pub-id><?supplied-pmid 25204227?><pub-id pub-id-type="pmid">25204227</pub-id></element-citation></ref><ref id="B88-antibiotics-09-00325"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wozniak</surname><given-names>L.</given-names></name><name><surname>Skapska</surname><given-names>S.</given-names></name><name><surname>Marszalek</surname><given-names>K.</given-names></name></person-group><article-title>Ursolic acid---A pentacyclic triterpenoid with a wide spectrum of pharmacological activities</article-title><source>Molecules</source><year>2015</year><volume>20</volume><fpage>20614</fpage><lpage>20641</lpage><pub-id pub-id-type="doi">10.3390/molecules201119721</pub-id><?supplied-pmid 26610440?><pub-id pub-id-type="pmid">26610440</pub-id></element-citation></ref><ref id="B89-antibiotics-09-00325"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>U.</given-names></name><name><surname>Jacobo-Herrera</surname><given-names>N.</given-names></name><name><surname>Altemimi</surname><given-names>A.</given-names></name><name><surname>Lakhssassi</surname><given-names>N.</given-names></name></person-group><article-title>A comprehensive review on medicinal plants as antimicrobial therapeutics: Potential avenues of biocompatible drug discovery</article-title><source>Metabolites</source><year>2019</year><volume>9</volume><elocation-id>258</elocation-id><pub-id pub-id-type="doi">10.3390/metabo9110258</pub-id><?supplied-pmid 31683833?><pub-id pub-id-type="pmid">31683833</pub-id></element-citation></ref><ref id="B90-antibiotics-09-00325"><label>90.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ludwiczuk</surname><given-names>A.</given-names></name><name><surname>Skalicka-Wo&#x0017a;niak</surname><given-names>K.</given-names></name><name><surname>Georgiev</surname><given-names>M.</given-names></name></person-group><article-title>Terpenoids</article-title><source>Pharmacognosy</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2017</year><fpage>233</fpage><lpage>266</lpage></element-citation></ref><ref id="B91-antibiotics-09-00325"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashour</surname><given-names>M.</given-names></name><name><surname>Wink</surname><given-names>M.</given-names></name><name><surname>Gershenzon</surname><given-names>J.</given-names></name></person-group><article-title>Biochemistry of terpenoids: Monoterpenes, sesquiterpenes and diterpenes</article-title><source>Annu. Plant Rev.</source><year>2018</year><volume>40</volume><fpage>258</fpage><lpage>303</lpage></element-citation></ref><ref id="B92-antibiotics-09-00325"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guimaraes</surname><given-names>A.C.</given-names></name><name><surname>Meireles</surname><given-names>L.M.</given-names></name><name><surname>Lemos</surname><given-names>M.F.</given-names></name><name><surname>Guimaraes</surname><given-names>M.C.C.</given-names></name><name><surname>Endringer</surname><given-names>D.C.</given-names></name><name><surname>Fronza</surname><given-names>M.</given-names></name><name><surname>Scherer</surname><given-names>R.</given-names></name></person-group><article-title>Antibacterial activity of terpenes and terpenoids present in essential oils</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>2471</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24132471</pub-id></element-citation></ref><ref id="B93-antibiotics-09-00325"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>L.L.</given-names></name><name><surname>Wang</surname><given-names>S.F.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>K.</given-names></name></person-group><article-title>Anti-inflammatory terpenoids from the leaves and twigs of Dysoxylum gotadhora</article-title><source>J. Nat. Prod.</source><year>2015</year><volume>78</volume><fpage>1037</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1021/np5010196</pub-id><pub-id pub-id-type="pmid">25945867</pub-id></element-citation></ref><ref id="B94-antibiotics-09-00325"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nothias-Scaglia</surname><given-names>L.F.</given-names></name><name><surname>Pannecouque</surname><given-names>C.</given-names></name><name><surname>Renucci</surname><given-names>F.</given-names></name><name><surname>Delang</surname><given-names>L.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name><name><surname>Roussi</surname><given-names>F.</given-names></name><name><surname>Costa</surname><given-names>J.</given-names></name><name><surname>Leyssen</surname><given-names>P.</given-names></name><name><surname>Litaudon</surname><given-names>M.</given-names></name><name><surname>Paolini</surname><given-names>J.</given-names></name></person-group><article-title>Antiviral activity of diterpene esters on chikungunya virus and hiv replication</article-title><source>J. Nat. Prod.</source><year>2015</year><volume>78</volume><fpage>1277</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.5b00073</pub-id><pub-id pub-id-type="pmid">25970561</pub-id></element-citation></ref><ref id="B95-antibiotics-09-00325"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alqahtani</surname><given-names>A.</given-names></name><name><surname>Hamid</surname><given-names>K.</given-names></name><name><surname>Kam</surname><given-names>A.</given-names></name><name><surname>Wong</surname><given-names>K.H.</given-names></name><name><surname>Abdelhak</surname><given-names>Z.</given-names></name><name><surname>Razmovski-Naumovski</surname><given-names>V.</given-names></name><name><surname>Chan</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Groundwater</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name></person-group><article-title>The pentacyclic triterpenoids in herbal medicines and their pharmacological activities in diabetes and diabetic complications</article-title><source>Curr. Med. Chem.</source><year>2012</year><volume>20</volume><fpage>908</fpage><lpage>931</lpage></element-citation></ref><ref id="B96-antibiotics-09-00325"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>X.L.</given-names></name><name><surname>Mao</surname><given-names>X.X.</given-names></name><name><surname>Du</surname><given-names>Y.M.</given-names></name><name><surname>Yan</surname><given-names>P.Z.</given-names></name><name><surname>Hou</surname><given-names>X.D.</given-names></name><name><surname>Zhang</surname><given-names>Z.F.</given-names></name></person-group><article-title>Anti-tumor activity of cembranoid-type diterpenes isolated from <italic>Nicotiana tabacum</italic> L.</article-title><source>Biomoleculars</source><year>2019</year><volume>9</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.3390/biom9020045</pub-id></element-citation></ref><ref id="B97-antibiotics-09-00325"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quaglio</surname><given-names>D.</given-names></name><name><surname>Corradi</surname><given-names>S.</given-names></name><name><surname>Erazo</surname><given-names>S.</given-names></name><name><surname>Vergine</surname><given-names>V.</given-names></name><name><surname>Berardozzi</surname><given-names>S.</given-names></name><name><surname>Sciubba</surname><given-names>F.</given-names></name><name><surname>Cappiello</surname><given-names>F.</given-names></name><name><surname>Crestoni</surname><given-names>M.E.</given-names></name><name><surname>Ascenzioni</surname><given-names>F.</given-names></name><name><surname>Imperi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Structural elucidation and antimicrobial characterization of novel diterpenoids from <italic>Fabiana densa</italic> var</article-title><source>Ramulosa. ACS Med. Chem. Lett.</source><year>2020</year><volume>11</volume><fpage>760</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.9b00605</pub-id><?supplied-pmid 32435382?><pub-id pub-id-type="pmid">32435382</pub-id></element-citation></ref><ref id="B98-antibiotics-09-00325"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imane</surname><given-names>N.I.</given-names></name><name><surname>Fouzia</surname><given-names>H.</given-names></name><name><surname>Azzahra</surname><given-names>L.F.</given-names></name><name><surname>Ahmed</surname><given-names>E.</given-names></name><name><surname>Ismail</surname><given-names>G.</given-names></name><name><surname>Idrissa</surname><given-names>D.</given-names></name><name><surname>Mohamed</surname><given-names>K.-H.</given-names></name><name><surname>Sirine</surname><given-names>F.</given-names></name><name><surname>L&#x02019;Houcine</surname><given-names>O.</given-names></name><name><surname>Noureddine</surname><given-names>B.</given-names></name></person-group><article-title>Chemical composition, antibacterial and antioxidant activities of some essential oils against multidrug resistant bacteria</article-title><source>Eur. J. Integr. Med.</source><year>2020</year><volume>35</volume><fpage>101074</fpage><pub-id pub-id-type="doi">10.1016/j.eujim.2020.101074</pub-id></element-citation></ref><ref id="B99-antibiotics-09-00325"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langeveld</surname><given-names>W.T.</given-names></name><name><surname>Veldhuizen</surname><given-names>E.J.</given-names></name><name><surname>Burt</surname><given-names>S.A.</given-names></name></person-group><article-title>Synergy between essential oil components and antibiotics: A review</article-title><source>Crit. Rev. Microbiol.</source><year>2014</year><volume>40</volume><fpage>76</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.3109/1040841X.2013.763219</pub-id><?supplied-pmid 23445470?><pub-id pub-id-type="pmid">23445470</pub-id></element-citation></ref><ref id="B100-antibiotics-09-00325"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>P.S.</given-names></name><name><surname>Lim</surname><given-names>S.H.</given-names></name><name><surname>Hu</surname><given-names>C.P.</given-names></name><name><surname>Yiap</surname><given-names>B.C.</given-names></name></person-group><article-title>Combination of essential oils and antibiotics reduce antibiotic resistance in plasmid-conferred multidrug resistant bacteria</article-title><source>Phytomedicine</source><year>2013</year><volume>20</volume><fpage>710</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2013.02.013</pub-id><?supplied-pmid 23537749?><pub-id pub-id-type="pmid">23537749</pub-id></element-citation></ref><ref id="B101-antibiotics-09-00325"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thimmappa</surname><given-names>R.</given-names></name><name><surname>Geisler</surname><given-names>K.</given-names></name><name><surname>Louveau</surname><given-names>T.</given-names></name><name><surname>O&#x02019;Maille</surname><given-names>P.</given-names></name><name><surname>Osbourn</surname><given-names>A.</given-names></name></person-group><article-title>Triterpene biosynthesis in plants</article-title><source>Annu. Rev. Plant Biol.</source><year>2014</year><volume>65</volume><fpage>225</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1146/annurev-arplant-050312-120229</pub-id><pub-id pub-id-type="pmid">24498976</pub-id></element-citation></ref><ref id="B102-antibiotics-09-00325"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demetzos</surname><given-names>C.</given-names></name><name><surname>Dimas</surname><given-names>K.</given-names></name></person-group><article-title>Labdane-type diterpenes: Chemistry and biological activity</article-title><source>Stud. Nat. Prod. Chem.</source><year>2001</year><volume>25</volume><fpage>235</fpage><lpage>292</lpage></element-citation></ref><ref id="B103-antibiotics-09-00325"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>R.S.L.</given-names></name><name><surname>Towers</surname><given-names>G.H.N.</given-names></name></person-group><article-title>Antibacterial constituents of the nepalese medicinal herb, <italic>Centipeda Minima</italic></article-title><source>Phytochemistry</source><year>1998</year><volume>47</volume><fpage>631</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(97)00534-7</pub-id><pub-id pub-id-type="pmid">9461679</pub-id></element-citation></ref><ref id="B104-antibiotics-09-00325"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawazoe</surname><given-names>K.</given-names></name><name><surname>Tsubouchi</surname><given-names>Y.</given-names></name><name><surname>Abdullah</surname><given-names>N.</given-names></name><name><surname>Takaishi</surname><given-names>Y.</given-names></name><name><surname>Shibata</surname><given-names>H.</given-names></name><name><surname>Higuti</surname><given-names>T.</given-names></name><name><surname>Hori</surname><given-names>H.</given-names></name><name><surname>Ogawa</surname><given-names>M.</given-names></name></person-group><article-title>Sesquiterpenoids from <italic>Artemisia gilvescens</italic> and an anti-mrsa compound</article-title><source>J. Nat. Prod.</source><year>2003</year><volume>66</volume><fpage>538</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1021/np020593m</pub-id><pub-id pub-id-type="pmid">12713410</pub-id></element-citation></ref><ref id="B105-antibiotics-09-00325"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ordonez</surname><given-names>P.E.</given-names></name><name><surname>Quave</surname><given-names>C.L.</given-names></name><name><surname>Reynolds</surname><given-names>W.F.</given-names></name><name><surname>Varughese</surname><given-names>K.I.</given-names></name><name><surname>Berry</surname><given-names>B.</given-names></name><name><surname>Breen</surname><given-names>P.J.</given-names></name><name><surname>Malagon</surname><given-names>O.</given-names></name><name><surname>Vidari</surname><given-names>G.</given-names></name><name><surname>Smeltzer</surname><given-names>M.S.</given-names></name><name><surname>Compadre</surname><given-names>C.M.</given-names></name></person-group><article-title>Sesquiterpene lactones from Gynoxys verrucosa and their anti-mrsa activity</article-title><source>J. Ethnopharmacol.</source><year>2011</year><volume>137</volume><fpage>1055</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.07.012</pub-id><pub-id pub-id-type="pmid">21782013</pub-id></element-citation></ref><ref id="B106-antibiotics-09-00325"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mustaffa</surname><given-names>F.</given-names></name><name><surname>Indurkar</surname><given-names>J.</given-names></name><name><surname>Ismail</surname><given-names>S.</given-names></name><name><surname>Shah</surname><given-names>M.</given-names></name><name><surname>Mansor</surname><given-names>S.M.</given-names></name></person-group><article-title>An antimicrobial compound isolated from <italic>Cinnamomum iners</italic> leaves with activity against methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Molecules</source><year>2011</year><volume>16</volume><fpage>3037</fpage><lpage>3047</lpage><pub-id pub-id-type="doi">10.3390/molecules16043037</pub-id><pub-id pub-id-type="pmid">21478819</pub-id></element-citation></ref><ref id="B107-antibiotics-09-00325"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corlay</surname><given-names>N.</given-names></name><name><surname>Lecso-Bornet</surname><given-names>M.</given-names></name><name><surname>Leborgne</surname><given-names>E.</given-names></name><name><surname>Blanchard</surname><given-names>F.</given-names></name><name><surname>Cachet</surname><given-names>X.</given-names></name><name><surname>Bignon</surname><given-names>J.</given-names></name><name><surname>Roussi</surname><given-names>F.</given-names></name><name><surname>Butel</surname><given-names>M.J.</given-names></name><name><surname>Awang</surname><given-names>K.</given-names></name><name><surname>Litaudon</surname><given-names>M.</given-names></name></person-group><article-title>Antibacterial labdane diterpenoids from <italic>Vitex vestita</italic></article-title><source>J. Nat. Prod.</source><year>2015</year><volume>78</volume><fpage>1348</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.5b00206</pub-id><pub-id pub-id-type="pmid">26034885</pub-id></element-citation></ref><ref id="B108-antibiotics-09-00325"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farimani</surname><given-names>M.M.</given-names></name><name><surname>Taleghani</surname><given-names>A.</given-names></name><name><surname>Aliabadi</surname><given-names>A.</given-names></name><name><surname>Aliahmadi</surname><given-names>A.</given-names></name><name><surname>Esmaeili</surname><given-names>M.A.</given-names></name><name><surname>Namazi Sarvestani</surname><given-names>N.</given-names></name><name><surname>Khavasi</surname><given-names>H.R.</given-names></name><name><surname>Smiesko</surname><given-names>M.</given-names></name><name><surname>Hamburger</surname><given-names>M.</given-names></name><name><surname>Nejad Ebrahimi</surname><given-names>S.</given-names></name></person-group><article-title>Labdane diterpenoids from Salvia leriifolia: Absolute configuration, antimicrobial and cytotoxic activities</article-title><source>Planta Med.</source><year>2016</year><volume>82</volume><fpage>1279</fpage><lpage>1285</lpage><pub-id pub-id-type="doi">10.1055/s-0042-107798</pub-id><?supplied-pmid 27280932?><pub-id pub-id-type="pmid">27280932</pub-id></element-citation></ref><ref id="B109-antibiotics-09-00325"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Duan</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Xue</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>A pair of epimeric cassane-type diterpenoids and a new labdane-type derivative from Caesalpinia decapetala</article-title><source>Tetrahedron</source><year>2018</year><volume>74</volume><fpage>3852</fpage><lpage>3857</lpage><pub-id pub-id-type="doi">10.1016/j.tet.2018.05.028</pub-id></element-citation></ref><ref id="B110-antibiotics-09-00325"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddique</surname><given-names>H.</given-names></name><name><surname>Pendry</surname><given-names>B.</given-names></name><name><surname>Rahman</surname><given-names>M.M.</given-names></name></person-group><article-title>Terpenes from <italic>Zingiber montanum</italic> and their screening against multi-drug resistant and methicillin resistant <italic>Staphylococcus aureus</italic></article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>385</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24030385</pub-id><?supplied-pmid 30678230?><pub-id pub-id-type="pmid">30678230</pub-id></element-citation></ref><ref id="B111-antibiotics-09-00325"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaspar-Marques</surname><given-names>C.</given-names></name><name><surname>Rijo</surname><given-names>P.</given-names></name><name><surname>Simoes</surname><given-names>M.F.</given-names></name><name><surname>Duarte</surname><given-names>M.A.</given-names></name><name><surname>Rodriguez</surname><given-names>B.</given-names></name></person-group><article-title>Abietanes from <italic>Plectranthus grandidentatus</italic> and <italic>P. hereroensis</italic> against methicillin- and vancomycin-resistant bacteria</article-title><source>Phytomedicine</source><year>2006</year><volume>13</volume><fpage>267</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2005.06.002</pub-id><pub-id pub-id-type="pmid">16492530</pub-id></element-citation></ref><ref id="B112-antibiotics-09-00325"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurkaninova</surname><given-names>S.</given-names></name><name><surname>Kubinova</surname><given-names>R.</given-names></name><name><surname>Nejezchlebova</surname><given-names>M.</given-names></name><name><surname>Gazdova</surname><given-names>M.</given-names></name><name><surname>Hanakova</surname><given-names>Z.</given-names></name><name><surname>Dall&#x02019;Acqua</surname><given-names>S.</given-names></name></person-group><article-title>Anti-mrsa activity of abietane diterpenes from <italic>Coleus blumei</italic> benth</article-title><source>Nat. Prod. Res.</source><year>2019</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1080/14786419.2019.1686371</pub-id></element-citation></ref><ref id="B113-antibiotics-09-00325"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porto</surname><given-names>T.S.</given-names></name><name><surname>Simao</surname><given-names>M.R.</given-names></name><name><surname>Carlos</surname><given-names>L.Z.</given-names></name><name><surname>Martins</surname><given-names>C.H.</given-names></name><name><surname>Furtado</surname><given-names>N.A.</given-names></name><name><surname>Said</surname><given-names>S.</given-names></name><name><surname>Arakawa</surname><given-names>N.S.</given-names></name><name><surname>dos Santos</surname><given-names>R.A.</given-names></name><name><surname>Veneziani</surname><given-names>R.C.</given-names></name><name><surname>Ambrosio</surname><given-names>S.R.</given-names></name></person-group><article-title>Pimarane-type diterpenes obtained by biotransformation: Antimicrobial properties against clinically isolated gram-positive multidrug-resistant bacteria</article-title><source>Phytother. Res.</source><year>2013</year><volume>27</volume><fpage>1502</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1002/ptr.4887</pub-id><pub-id pub-id-type="pmid">23193079</pub-id></element-citation></ref><ref id="B114-antibiotics-09-00325"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stavri</surname><given-names>M.</given-names></name><name><surname>Paton</surname><given-names>A.</given-names></name><name><surname>Skelton</surname><given-names>B.W.</given-names></name><name><surname>Gibbons</surname><given-names>S.</given-names></name></person-group><article-title>Antibacterial diterpenes from <italic>Plectranthus ernstii</italic></article-title><source>J. Nat. Prod.</source><year>2009</year><volume>72</volume><fpage>1191</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1021/np800581s</pub-id><pub-id pub-id-type="pmid">19445517</pub-id></element-citation></ref><ref id="B115-antibiotics-09-00325"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>E.</given-names></name><name><surname>Williamson</surname><given-names>E.</given-names></name><name><surname>Zloh</surname><given-names>M.</given-names></name><name><surname>Gibbons</surname><given-names>S.</given-names></name></person-group><article-title>Isopimaric acid from <italic>Pinus nigra</italic> shows activity against multidrug-resistant and emrsa strains of <italic>Staphylococcus aureus</italic></article-title><source>Phytother. Res.</source><year>2005</year><volume>19</volume><fpage>538</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1002/ptr.1711</pub-id><pub-id pub-id-type="pmid">16114093</pub-id></element-citation></ref><ref id="B116-antibiotics-09-00325"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soares</surname><given-names>A.C.F.</given-names></name><name><surname>Matos</surname><given-names>P.M.</given-names></name><name><surname>Silva</surname><given-names>K.F.d.</given-names></name><name><surname>Martins</surname><given-names>C.H.G.</given-names></name><name><surname>Veneziani</surname><given-names>R.C.S.</given-names></name><name><surname>Ambr&#x000f3;sio</surname><given-names>S.R.</given-names></name><name><surname>Dias</surname><given-names>H.J.</given-names></name><name><surname>Santos</surname><given-names>R.A.d.</given-names></name><name><surname>Heleno</surname><given-names>V.C.G.</given-names></name></person-group><article-title>Antimicrobial potential of natural and semi-synthetic ent-kaurane and ent-pimarane diterpenes against clinically isolated gram-positive multidrug-resistant bacteria</article-title><source>J. Braz. Chem. Soc.</source><year>2019</year><volume>30</volume><fpage>333</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.21577/0103-5053.20180182</pub-id></element-citation></ref><ref id="B117-antibiotics-09-00325"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeifer Barbosa</surname><given-names>A.L.</given-names></name><name><surname>Wenzel-Storjohann</surname><given-names>A.</given-names></name><name><surname>Barbosa</surname><given-names>J.D.</given-names></name><name><surname>Zidorn</surname><given-names>C.</given-names></name><name><surname>Peifer</surname><given-names>C.</given-names></name><name><surname>Tasdemir</surname><given-names>D.</given-names></name><name><surname>Cicek</surname><given-names>S.S.</given-names></name></person-group><article-title>Antimicrobial and cytotoxic effects of the <italic>Copaifera reticulata</italic> oleoresin and its main diterpene acids</article-title><source>J. Ethnopharmacol.</source><year>2019</year><volume>233</volume><fpage>94</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2018.11.029</pub-id><pub-id pub-id-type="pmid">30472403</pub-id></element-citation></ref><ref id="B118-antibiotics-09-00325"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghirga</surname><given-names>F.S.R.</given-names></name><name><surname>Cavinato</surname><given-names>L.</given-names></name><name><surname>Lo Sciuto</surname><given-names>A.</given-names></name><name><surname>Corradi</surname><given-names>S.</given-names></name><name><surname>Quaglio</surname><given-names>D.</given-names></name><name><surname>Calcaterra</surname><given-names>A.</given-names></name><name><surname>Casciaro</surname><given-names>B.</given-names></name><name><surname>Loffredo</surname><given-names>M.R.</given-names></name><name><surname>Cappiello</surname><given-names>F.</given-names></name><name><surname>Morelli</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A novel colistin adjuvant identified by virtual screening for arnt inhibitors</article-title><source>J. Antimicrob. Chem.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/jac/dkaa200</pub-id><?supplied-pmid 32514531?><pub-id pub-id-type="pmid">32514531</pub-id></element-citation></ref><ref id="B119-antibiotics-09-00325"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pooi Yin</surname><given-names>C.</given-names></name><name><surname>Navaratnam</surname><given-names>P.</given-names></name><name><surname>Chung</surname><given-names>L.Y.</given-names></name></person-group><article-title>Synergistic antimicrobial activity between pentacyclic triterpenoids and antibiotics against <italic>Staphylococcus aureus</italic> strains</article-title><source>Annals Clin. Microbial. Antimicrob.</source><year>2011</year><volume>10</volume><fpage>25</fpage></element-citation></ref><ref id="B120-antibiotics-09-00325"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horiuchi</surname><given-names>K.</given-names></name><name><surname>Shiota</surname><given-names>S.</given-names></name><name><surname>Hatano</surname><given-names>T.</given-names></name><name><surname>Yoshida</surname><given-names>T.</given-names></name><name><surname>Kuroda</surname><given-names>T.</given-names></name><name><surname>Tsuchiya</surname><given-names>T.</given-names></name></person-group><article-title>Antimicrobial activity of oleanolic acid from <italic>Salvia officinalis</italic> and related compounds on vancomycin-resistant enterococci (vre)</article-title><source>Biol. Pharm. Bull.</source><year>2007</year><volume>30</volume><fpage>1147</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1248/bpb.30.1147</pub-id><?supplied-pmid 17541170?><pub-id pub-id-type="pmid">17541170</pub-id></element-citation></ref><ref id="B121-antibiotics-09-00325"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwivedi</surname><given-names>G.R.</given-names></name><name><surname>Maurya</surname><given-names>A.</given-names></name><name><surname>Yadav</surname><given-names>D.K.</given-names></name><name><surname>Khan</surname><given-names>F.</given-names></name><name><surname>Darokar</surname><given-names>M.P.</given-names></name><name><surname>Srivastava</surname><given-names>S.K.</given-names></name></person-group><article-title>Drug resistance reversal potential of ursolic acid derivatives against nalidixic acid- and multidrug-resistant <italic>Escherichia. coli</italic></article-title><source>Chem. Biol. Drug Des.</source><year>2015</year><volume>86</volume><fpage>272</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1111/cbdd.12491</pub-id><?supplied-pmid 25476148?><pub-id pub-id-type="pmid">25476148</pub-id></element-citation></ref><ref id="B122-antibiotics-09-00325"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.M.</given-names></name><name><surname>Chen</surname><given-names>H.T.</given-names></name><name><surname>Wu</surname><given-names>Z.Y.</given-names></name><name><surname>Jhan</surname><given-names>Y.L.</given-names></name><name><surname>Shyu</surname><given-names>C.L.</given-names></name><name><surname>Chou</surname><given-names>C.H.</given-names></name></person-group><article-title>Antibacterial and synergistic activity of pentacyclic triterpenoids isolated from <italic>Alstonia scholaris</italic></article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>139</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21020139</pub-id><?supplied-pmid 26821000?><pub-id pub-id-type="pmid">26821000</pub-id></element-citation></ref><ref id="B123-antibiotics-09-00325"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>B.G.</given-names></name><name><surname>Rodrigues Teixeira</surname><given-names>A.M.</given-names></name><name><surname>Silva</surname><given-names>P.T.D.</given-names></name><name><surname>Vasconcelos Evaristo</surname><given-names>F.F.</given-names></name><name><surname>de Vaconcelos</surname><given-names>M.A.</given-names></name><name><surname>Holanda Teixeira</surname><given-names>E.</given-names></name><name><surname>Dos Santos</surname><given-names>H.S.</given-names></name><name><surname>Bandeira</surname><given-names>P.N.</given-names></name><name><surname>Sena-Junior</surname><given-names>D.M.</given-names></name><name><surname>Barreto</surname><given-names>V.P.</given-names></name><etal/></person-group><article-title>Antimicrobial activity of the lupane triterpene 3beta,6beta,16beta-trihydroxylup-20(29)-ene isolated from <italic>Combretum leprosum</italic> mart</article-title><source>J. Med. Microbiol.</source><year>2019</year><volume>68</volume><fpage>1438</fpage><lpage>1444</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.001056</pub-id><pub-id pub-id-type="pmid">31385784</pub-id></element-citation></ref><ref id="B124-antibiotics-09-00325"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez-Lugo</surname><given-names>M.T.</given-names></name><name><surname>Singh</surname><given-names>M.P.</given-names></name><name><surname>Maiese</surname><given-names>W.M.</given-names></name><name><surname>Timmermann</surname><given-names>B.N.</given-names></name></person-group><article-title>New antimicrobial cycloartane triterpenes from <italic>Acalypha communis</italic></article-title><source>J. Nat. Prod.</source><year>2002</year><volume>65</volume><fpage>872</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1021/np020044g</pub-id><pub-id pub-id-type="pmid">12088430</pub-id></element-citation></ref><ref id="B125-antibiotics-09-00325"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.Y.</given-names></name><name><surname>Tang</surname><given-names>G.H.</given-names></name><name><surname>Yuan</surname><given-names>C.M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zou</surname><given-names>T.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Hao</surname><given-names>X.J.</given-names></name><name><surname>He</surname><given-names>H.P.</given-names></name></person-group><article-title>Aphagrandinoids a-d, cycloartane triterpenoids with antibacterial activities from <italic>Aphanamix. grandifolia</italic></article-title><source>Fitoterapia</source><year>2013</year><volume>85</volume><fpage>64</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2012.12.030</pub-id><pub-id pub-id-type="pmid">23313271</pub-id></element-citation></ref><ref id="B126-antibiotics-09-00325"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosa</surname><given-names>R.</given-names></name><name><surname>Mandlakayise</surname><given-names>L.</given-names></name><name><surname>Thandeka</surname><given-names>V.</given-names></name><name><surname>Andy</surname><given-names>R.</given-names></name></person-group><article-title>Antibacterial activity of two triterpenes from stem bark of <italic>Protorhus longifolia</italic></article-title><source>J. Med. Plant. Res.</source><year>2014</year><volume>8</volume><fpage>686</fpage><lpage>702</lpage></element-citation></ref><ref id="B127-antibiotics-09-00325"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C.</given-names></name><name><surname>Hesek</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Mobashery</surname><given-names>S.</given-names></name></person-group><article-title>Potentiation of the activity of beta-lactam antibiotics by farnesol and its derivatives</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2018</year><volume>28</volume><fpage>642</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2018.01.028</pub-id><pub-id pub-id-type="pmid">29402738</pub-id></element-citation></ref><ref id="B128-antibiotics-09-00325"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>V.K.</given-names></name><name><surname>Verma</surname><given-names>S.</given-names></name><name><surname>Pal</surname><given-names>A.</given-names></name><name><surname>Srivastava</surname><given-names>S.K.</given-names></name><name><surname>Srivastava</surname><given-names>P.K.</given-names></name><name><surname>Darokar</surname><given-names>M.P.</given-names></name></person-group><article-title>In vivo efficacy and synergistic interaction of 16alpha-hydroxycleroda-3, 13 (14) z-dien-15, 16-olide, a clerodane diterpene from <italic>Polyalthia longifolia</italic> against methicillin-resistant <italic>Staphylococcus saureus</italic></article-title><source>Appl. Microbiol. Biotechnol.</source><year>2013</year><volume>97</volume><fpage>9121</fpage><lpage>9131</lpage><pub-id pub-id-type="doi">10.1007/s00253-013-5154-9</pub-id><?supplied-pmid 23989974?><pub-id pub-id-type="pmid">23989974</pub-id></element-citation></ref><ref id="B129-antibiotics-09-00325"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayout</surname><given-names>A.</given-names></name><name><surname>Ouarhach</surname><given-names>A.</given-names></name><name><surname>Rabie</surname><given-names>R.</given-names></name><name><surname>Dilagui</surname><given-names>I.</given-names></name><name><surname>Soraa</surname><given-names>N.</given-names></name><name><surname>Romane</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation of antibacterial activity of <italic>lavandula pedunculata</italic> subsp. atlantica (braun-blanq.) romo essential oil and selected terpenoids against resistant bacteria strains-structure-activity relationships</article-title><source>Chem. Biodivers.</source><year>2020</year><volume>17</volume><fpage>e1900496</fpage><pub-id pub-id-type="doi">10.1002/cbdv.201900496</pub-id><?supplied-pmid 31909551?><pub-id pub-id-type="pmid">31909551</pub-id></element-citation></ref><ref id="B130-antibiotics-09-00325"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenzi</surname><given-names>V.</given-names></name><name><surname>Muselli</surname><given-names>A.</given-names></name><name><surname>Bernardini</surname><given-names>A.F.</given-names></name><name><surname>Berti</surname><given-names>L.</given-names></name><name><surname>Pages</surname><given-names>J.M.</given-names></name><name><surname>Amaral</surname><given-names>L.</given-names></name><name><surname>Bolla</surname><given-names>J.M.</given-names></name></person-group><article-title>Geraniol restores antibiotic activities against multidrug-resistant isolates from gram-negative species</article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>2209</fpage><lpage>2211</lpage><pub-id pub-id-type="doi">10.1128/AAC.00919-08</pub-id><?supplied-pmid 19258278?><pub-id pub-id-type="pmid">19258278</pub-id></element-citation></ref><ref id="B131-antibiotics-09-00325"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Breij</surname><given-names>A.</given-names></name><name><surname>Karnaoukh</surname><given-names>T.G.</given-names></name><name><surname>Schrumpf</surname><given-names>J.</given-names></name><name><surname>Hiemstra</surname><given-names>P.S.</given-names></name><name><surname>Nibbering</surname><given-names>P.H.</given-names></name><name><surname>van Dissel</surname><given-names>J.T.</given-names></name><name><surname>de Visser</surname><given-names>P.C.</given-names></name></person-group><article-title>The licorice pentacyclic triterpenoid component 18beta-glycyrrhetinic acid enhances the activity of antibiotics against strains of methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2016</year><volume>35</volume><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1007/s10096-015-2570-z</pub-id><?supplied-pmid 26780691?><pub-id pub-id-type="pmid">26780691</pub-id></element-citation></ref><ref id="B132-antibiotics-09-00325"><label>132.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>W.F.</given-names></name><name><surname>Enriquez</surname><given-names>R.G.</given-names></name></person-group><article-title>Terpenes: Mono-, sesqui-, and higher Terpenes</article-title><source>Modern NMR Approaches to the Structure Elucidation of Natural Products: Volume 2: Data Acquisition and Applications to Compound Classes</source><publisher-name>The Royal Society of Chemistry</publisher-name><publisher-loc>Cambridge, UK</publisher-loc><year>2017</year></element-citation></ref><ref id="B133-antibiotics-09-00325"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>S.G.</given-names></name><name><surname>Wyllie</surname><given-names>S.G.</given-names></name><name><surname>Markham</surname><given-names>J.L.</given-names></name><name><surname>Leach</surname><given-names>D.N.</given-names></name></person-group><article-title>The role of structure and molecular properties of terpenoids in determining their antimicrobial activity</article-title><source>Flavour Fragr. J.</source><year>1999</year><volume>14</volume><fpage>322</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1099-1026(199909/10)14:5&#x0003c;322::AID-FFJ837&#x0003e;3.0.CO;2-4</pub-id></element-citation></ref><ref id="B134-antibiotics-09-00325"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahizan</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>S.K.</given-names></name><name><surname>Moo</surname><given-names>C.-L.</given-names></name><name><surname>Song</surname><given-names>A.</given-names></name><name><surname>Chong</surname><given-names>C.M.</given-names></name><name><surname>Chong</surname><given-names>C.</given-names></name><name><surname>Abushelaibi</surname><given-names>A.</given-names></name><name><surname>Lim</surname><given-names>E.</given-names></name><name><surname>Lai</surname><given-names>K.-S.</given-names></name></person-group><article-title>Terpene derivatives as a potential agent against antimicrobial resistance (amr) pathogens</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>2631</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24142631</pub-id></element-citation></ref><ref id="B135-antibiotics-09-00325"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayout</surname><given-names>A.</given-names></name><name><surname>Ouarhach</surname><given-names>A.</given-names></name><name><surname>Dilagui</surname><given-names>I.</given-names></name><name><surname>Soraa</surname><given-names>N.</given-names></name><name><surname>Romane</surname><given-names>A.</given-names></name></person-group><article-title>Antibacterial activity and chemical composition of essential oil from <italic>Lavandula tenuisecta</italic> coss.Ex ball. An endemic species from Morocco</article-title><source>Eur. J. Integrative Med.</source><year>2020</year><volume>33</volume><fpage>101017</fpage><pub-id pub-id-type="doi">10.1016/j.eujim.2019.101017</pub-id></element-citation></ref><ref id="B136-antibiotics-09-00325"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brilhante</surname><given-names>R.S.</given-names></name><name><surname>Valente</surname><given-names>L.G.</given-names></name><name><surname>Rocha</surname><given-names>M.F.</given-names></name><name><surname>Bandeira</surname><given-names>T.J.</given-names></name><name><surname>Cordeiro</surname><given-names>R.A.</given-names></name><name><surname>Lima</surname><given-names>R.A.</given-names></name><name><surname>Leite</surname><given-names>J.J.</given-names></name><name><surname>Ribeiro</surname><given-names>J.F.</given-names></name><name><surname>Pereira</surname><given-names>J.F.</given-names></name><name><surname>Castelo-Branco</surname><given-names>D.S.</given-names></name><etal/></person-group><article-title>Sesquiterpene farnesol contributes to increased susceptibility to beta-lactams in strains of <italic>Burkholderia pseudomallei</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>2198</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1128/AAC.05885-11</pub-id><pub-id pub-id-type="pmid">22290941</pub-id></element-citation></ref><ref id="B137-antibiotics-09-00325"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo-Hsiung</surname><given-names>L.</given-names></name><name><surname>Ibuka</surname><given-names>T.</given-names></name><name><surname>Rong-Yang</surname><given-names>W.</given-names></name><name><surname>Geissman</surname><given-names>T.A.</given-names></name></person-group><article-title>Structure-antimicrobial activity relationships among the sesquiterpene lactones and related compounds</article-title><source>Phytochemistry</source><year>1977</year><volume>16</volume><fpage>1177</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(00)94355-3</pub-id></element-citation></ref><ref id="B138-antibiotics-09-00325"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibbons</surname><given-names>S.</given-names></name></person-group><article-title>Anti-staphylococcal plant natural products</article-title><source>Nat. Prod. Rep.</source><year>2004</year><volume>21</volume><fpage>263</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1039/b212695h</pub-id><pub-id pub-id-type="pmid">15042149</pub-id></element-citation></ref><ref id="B139-antibiotics-09-00325"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gon&#x000e7;alves</surname><given-names>O.</given-names></name><name><surname>Pereira</surname><given-names>R.</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>F.</given-names></name><name><surname>Mendo</surname><given-names>S.</given-names></name><name><surname>Coimbra</surname><given-names>M.A.</given-names></name><name><surname>Rocha</surname><given-names>S.M.</given-names></name></person-group><article-title>Evaluation of the mutagenicity of sesquiterpenic compounds and their influence on the susceptibility towards antibiotics of two clinically relevant bacterial strains</article-title><source>Mutat. Res./Genet. Toxicol. Environ. Mutagen.</source><year>2011</year><volume>723</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.mrgentox.2011.03.010</pub-id><?supplied-pmid 21453784?><pub-id pub-id-type="pmid">21453784</pub-id></element-citation></ref><ref id="B140-antibiotics-09-00325"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veneziani</surname><given-names>R.</given-names></name><name><surname>Ambrosio</surname><given-names>S.</given-names></name><name><surname>Martins</surname><given-names>C.H.</given-names></name><name><surname>Lemes</surname><given-names>D.C.</given-names></name><name><surname>Oliveira</surname><given-names>L.C.</given-names></name></person-group><article-title>Antibacterial potential of diterpenoids</article-title><source>Stud. Nat. Prod. Chem.</source><year>2017</year><volume>54</volume><fpage>109</fpage><lpage>139</lpage></element-citation></ref><ref id="B141-antibiotics-09-00325"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>V.K.</given-names></name><name><surname>Tiwari</surname><given-names>N.</given-names></name><name><surname>Gupta</surname><given-names>P.</given-names></name><name><surname>Verma</surname><given-names>S.</given-names></name><name><surname>Pal</surname><given-names>A.</given-names></name><name><surname>Srivastava</surname><given-names>S.K.</given-names></name><name><surname>Darokar</surname><given-names>M.P.</given-names></name></person-group><article-title>A clerodane diterpene from Polyalthia longifolia as a modifying agent of the resistance of methicillin resistant Staphylococcus aureus</article-title><source>Phytomedicine</source><year>2016</year><volume>23</volume><fpage>654</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2016.03.001</pub-id><?supplied-pmid 27161406?><pub-id pub-id-type="pmid">27161406</pub-id></element-citation></ref><ref id="B142-antibiotics-09-00325"><label>142.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Neto</surname><given-names>&#x000cd;.</given-names></name><name><surname>Faustino</surname><given-names>C.</given-names></name><name><surname>Rijo</surname><given-names>P.</given-names></name></person-group><article-title>Antimicrobial abietane diterpenoids against resistant bacteria and biofilms</article-title><source>The Battle Against Microbial Pathogens: Basic Science, Technological Advances and Educational Programs</source><person-group person-group-type="editor"><name><surname>M&#x000e9;ndez-Vilas</surname><given-names>A.</given-names></name></person-group><publisher-name>Formatex Research Center</publisher-name><publisher-loc>Badajoz, Spain</publisher-loc><year>2015</year><volume>Volume 1</volume><fpage>15</fpage><lpage>26</lpage></element-citation></ref><ref id="B143-antibiotics-09-00325"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urzua</surname><given-names>A.</given-names></name><name><surname>Rezende</surname><given-names>M.C.</given-names></name><name><surname>Mascayano</surname><given-names>C.</given-names></name><name><surname>Vasquez</surname><given-names>L.</given-names></name></person-group><article-title>A structure-activity study of antibacterial diterpenoids</article-title><source>Molecules</source><year>2008</year><volume>13</volume><fpage>882</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.3390/molecules13040822</pub-id><pub-id pub-id-type="pmid">18463590</pub-id></element-citation></ref><ref id="B144-antibiotics-09-00325"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zloh</surname><given-names>M.</given-names></name><name><surname>Kaatz</surname><given-names>G.W.</given-names></name><name><surname>Gibbons</surname><given-names>S.</given-names></name></person-group><article-title>Inhibitors of multidrug resistance (mdr) have affinity for mdr substrates</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2004</year><volume>14</volume><fpage>881</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2003.12.015</pub-id><pub-id pub-id-type="pmid">15012986</pub-id></element-citation></ref><ref id="B145-antibiotics-09-00325"><label>145.</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Imperi</surname><given-names>F.</given-names></name><name><surname>Ascenzioni</surname><given-names>F.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name><name><surname>Ghirga</surname><given-names>F.</given-names></name><name><surname>Quaglio</surname><given-names>D.</given-names></name><name><surname>Corradi</surname><given-names>S.</given-names></name><name><surname>Lo Sciuto</surname><given-names>A.</given-names></name><name><surname>Botta</surname><given-names>B.</given-names></name><name><surname>Calcaterra</surname><given-names>A.</given-names></name><name><surname>Stefanelli</surname><given-names>R.</given-names></name></person-group><article-title>Inibitori della antibiotico-resistenza mediata da ArnT. IT102019000012888, 2019</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.uniroma1.it/it/brevetto/102019000012888">https://www.uniroma1.it/it/brevetto/102019000012888</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-15">(accessed on 15 May 2020)</date-in-citation></element-citation></ref><ref id="B146-antibiotics-09-00325"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>P.Y.</given-names></name></person-group><article-title>Novel targets of pentacyclic triterpenoids in <italic>Staphylococcus aureus</italic>: A systematic review</article-title><source>Phytomedicine</source><year>2019</year><volume>73</volume><fpage>152933</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2019.152933</pub-id><pub-id pub-id-type="pmid">31103429</pub-id></element-citation></ref><ref id="B147-antibiotics-09-00325"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catteau</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Van Bambeke</surname><given-names>F.</given-names></name><name><surname>Quetin-Leclercq</surname><given-names>J.</given-names></name></person-group><article-title>Natural and hemi-synthetic pentacyclic triterpenes as antimicrobials and resistance modifying agents against <italic>Staphylococcus aureus</italic>: A review</article-title><source>Phytochem. Rev.</source><year>2018</year><volume>17</volume><fpage>1129</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1007/s11101-018-9564-2</pub-id></element-citation></ref><ref id="B148-antibiotics-09-00325"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>S.</given-names></name><name><surname>Talla</surname><given-names>E.</given-names></name><name><surname>Matchawe</surname><given-names>C.</given-names></name><name><surname>Alembert</surname><given-names>T.T.</given-names></name><name><surname>Elisabeth</surname><given-names>Z.M.</given-names></name><name><surname>Sophie</surname><given-names>L.</given-names></name><name><surname>Luce</surname><given-names>V.E.</given-names></name><name><surname>Maurice</surname><given-names>T.F.</given-names></name><name><surname>Jo&#x000eb;l</surname><given-names>Y.</given-names></name><name><surname>Alex</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pentacyclic triterpenes and crude extracts with antimicrobial activity from <italic>Cameroonian brown propolis</italic> samples</article-title><source>J. Appl. Pharm. Sci.</source><year>2014</year><volume>4</volume><fpage>1</fpage><lpage>9</lpage></element-citation></ref></ref-list></back><floats-group><fig id="antibiotics-09-00325-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Schematic representation of the principal mechanisms of antibiotic resistance.</p></caption><graphic xlink:href="antibiotics-09-00325-g001"/></fig><table-wrap id="antibiotics-09-00325-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">antibiotics-09-00325-t001_Table 1</object-id><label>Table 1</label><caption><p>Plant-derived terpenes in clinical trials (CT). Includes Not yet recruiting, Recruiting, Enrolling by invitation, Active not recruiting, Suspended and Completed trials of these compounds, parent extracts, or derivatives, applied alone or as a mixture with other constituents. Determined from <uri xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</uri> on 14 May 2020.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Plant Source</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of CT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Medicinal Purposes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Andrographolide</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Andrographis paniculata</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Squamous Cell Carcinoma of Esophagus, Multiple Sclerosis, Cognitive Impairment, Migraine Disorders, Arthritis Rheumatoid, Acute Respiratory Infections.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B79-antibiotics-09-00325" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Artemisinin</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Artemisia annua</italic> L.
</td><td align="center" valign="middle" rowspan="1" colspan="1">161</td><td align="center" valign="middle" rowspan="1" colspan="1">Schizophrenia, Malaria, Plasmodium Falciparum Malaria, Malaria in Pregnancy, Uncomplicated Falciparum Malaria, Vivax Malaria, Human Papilloma Virus Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, Metastatic Breast Cancer, Cytomegalovirus Infections, Increased Drug Resistance, Colorectal Cancer, Bowel Cancer, HIV, G6PD Deficiency, <italic>Schistosoma Haematobium</italic> and <italic>Schistosoma Mansoni</italic>.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B64-antibiotics-09-00325" ref-type="bibr">64</xref>,<xref rid="B80-antibiotics-09-00325" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-09-00325" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Betulin</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Betula</italic> spp.</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Epidermolysis Bullosa, Wounds, Burns.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B82-antibiotics-09-00325" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Betulinic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Betula pubescens, Hypericum lanceolatum</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Dysplastic Nevus Syndrome, Anxiety, Psychological Stress.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B82-antibiotics-09-00325" ref-type="bibr">82</xref>,<xref rid="B83-antibiotics-09-00325" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Boswellic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Boswellia serrata</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Relapsing Remitting Multiple Sclerosis, Renal Stones, Knee Osteoarthritis, Joint Pain, Stiffness.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B79-antibiotics-09-00325" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Geraniol</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Cinnamomum</italic>
<break/>
<italic>tenuipilum, Valeriana officinalis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Coronary Artery Disease, Uterine Cervical Dysplasia, Papillomavirus Infections.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B84-antibiotics-09-00325" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ginkgolides</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Ginkgo biloba</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Intravenous Alteplase Thrombolysis, Neurological Improving, Allergy, Ischemic Stroke.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B85-antibiotics-09-00325" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gossypol</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Gossypium hirsutum</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">Recurrent Adrenocortical Carcinoma, Stage III and IV Adrenocortical Carcinoma, Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor, Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Follicular Lymphoma, Adenocarcinoma of the Prostate, Prostate Cancer, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Laryngeal Cancer, Brain and Central Nervous System Tumors.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B80-antibiotics-09-00325" ref-type="bibr">80</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Limonene</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Citrus</italic> spp., <break/><italic>Apium graveolens</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">Breast Cancer, Allergic Contact Dermatitis Due to Cosmetics, Obesity.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B86-antibiotics-09-00325" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lupeol</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Hymenocardia acida</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Acne.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B83-antibiotics-09-00325" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Triptolide</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Tripterygium wilfordii</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">HIV-infection/AIDS, Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Metastatic Colorectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B64-antibiotics-09-00325" ref-type="bibr">64</xref>,<xref rid="B85-antibiotics-09-00325" ref-type="bibr">85</xref>,<xref rid="B87-antibiotics-09-00325" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ursolic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Rosmarinus officinalis, Malus domestica, Salvia officinalis, Thymus vulgaris</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metabolic Syndrome X, Sarcopenia.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-antibiotics-09-00325" ref-type="bibr">88</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="antibiotics-09-00325-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">antibiotics-09-00325-t002_Table 2</object-id><label>Table 2</label><caption><p>Plant-derived terpenes approved for therapeutic use. Additional resources from <uri xlink:href="https://www.drugs.com/">https://www.drugs.com/</uri> and <uri xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</uri></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trade Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Plant Source</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Medicinal Purposes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Arglabin</td><td align="center" valign="middle" rowspan="1" colspan="1">Arglabin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Artemisia glabella</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Cancer chemotherapy.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B80-antibiotics-09-00325" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-09-00325" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Artemisinin</td><td align="center" valign="middle" rowspan="1" colspan="1">Artemisinin</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Artemisia annua</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Antiprotozoal agent: Antimalarial.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B80-antibiotics-09-00325" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-09-00325" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Docetaxel</td><td align="center" valign="middle" rowspan="1" colspan="1">Taxotere</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Taxus baccata</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Treatment of head, neck, stomach, lung, prostate, breast and ovarian cancers.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B79-antibiotics-09-00325" ref-type="bibr">79</xref>,<xref rid="B81-antibiotics-09-00325" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ingenol mebutate</td><td align="center" valign="middle" rowspan="1" colspan="1">Picato</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Euphorbia peplus</italic> L.</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinic keratosis.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B80-antibiotics-09-00325" ref-type="bibr">80</xref>,<xref rid="B87-antibiotics-09-00325" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Taxol<sup>&#x000ae;</sup>, Paxene<sup>&#x000ae;</sup>, Abraxane, Nanoxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Taxus brevifolia</italic> Nutt.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chemotherapeutic agent for many types of cancer.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-antibiotics-09-00325" ref-type="bibr">80</xref>,<xref rid="B89-antibiotics-09-00325" ref-type="bibr">89</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="antibiotics-09-00325-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">antibiotics-09-00325-t003_Table 3</object-id><label>Table 3</label><caption><p>Summary of triterpenes with antimicrobial activity against resistant strains.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Common Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Chemical<break/>Structure</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tested<break/>Microorganism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial<break/>Effect</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Monoterpenes</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Geraniol</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i001.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>E. aerogenes</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Efflux Pump Inhibitor</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Helichrysum italicum</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B130-antibiotics-09-00325" ref-type="bibr">130</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Camphor</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i002.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>S. aureus</italic><break/><italic>E. coli</italic><break/><italic>E. aerogenes</italic><break/><italic>P. aeruginosa</italic><break/><italic>K. pneumoniae</italic><break/><italic>K. oxytoca</italic><break/><italic>Salmonella</italic> spp.<break/><italic>A. baumannii</italic><break/><italic>E. cloacae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Lavandula pedunculata subsp.atlantica</italic> (BRAUN-BLANQ)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B129-antibiotics-09-00325" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Linalool</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i003.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>S. aureus</italic><break/><italic>E. coli</italic><break/><italic>P. aeruginosa</italic><break/><italic>K. pneumoniae</italic><break/><italic>K. oxytoca</italic><break/><italic>Salmonella</italic> spp.<break/>
<italic>A. baumannii</italic><break/><italic>E. cloacae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Lavandula pedunculata subsp.atlantica</italic> (BRAUN-BLANQ)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B129-antibiotics-09-00325" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Terpinen-4-ol</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i004.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>S. aureus</italic><break/><italic>E. coli</italic><break/><italic>P. aeruginosa</italic><break/><italic>K. pneumoniae</italic><break/><italic>K. oxytoca</italic><break/><italic>Salmonella</italic> spp.<break/>
<italic>A. baumannii</italic><break/><italic>E. cloacae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Lavandula pedunculata subsp.atlantica</italic> (BRAUN-BLANQ)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B129-antibiotics-09-00325" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">Borneol</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i005.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. aureus</italic>
<break/>
<italic>E. coli</italic>
<break/>
<italic>E. aerogenes</italic>
<break/>
<italic>P. aeruginosa</italic>
<break/>
<italic>K. pneumoniae</italic>
<break/>
<italic>K. oxytoca</italic>
<break/>
<italic>A. baumannii</italic>
<break/>
<italic>E. cloacae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Lavandula pedunculata subsp.atlantica</italic> (BRAUN-BLANQ)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B129-antibiotics-09-00325" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fenchone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i006.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>S. aureus</italic><break/><italic>E. coli</italic><break/><italic>E. aerogenes</italic><break/><italic>P. aeruginosa</italic><break/><italic>K. pneumoniae</italic><break/><italic>K. oxytoca</italic><break/><italic>Salmonella</italic> spp.<break/><italic>A. baumannii</italic><break/><italic>E. cloacae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Species:<break/><italic>Lavandula pedunculata subsp.atlantica</italic> (BRAUN-BLANQ)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-antibiotics-09-00325" ref-type="bibr">129</xref>]</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Sesquiterpenes</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Farnesyl amine 2</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i007.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S.aureus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B127-antibiotics-09-00325" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Farnesyl phosphoramidothioic acid 6</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i008.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. aureus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B127-antibiotics-09-00325" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">Arnicolide D</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i009.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA<break/>MSSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Centipeda minima</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B103-antibiotics-09-00325" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">Arnicolide C</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i010.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA<break/>MSSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Centipeda minima</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B103-antibiotics-09-00325" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">Guaianolide 5</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i011.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Artemisia gilvescens</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B104-antibiotics-09-00325" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">Dehydroleucodine</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i012.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Gynoxys verrucosa</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B105-antibiotics-09-00325" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xanthorrhizol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i013.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA<break/><italic>E. coli</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Species:<break/><italic>Cinnamomum iners</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-antibiotics-09-00325" ref-type="bibr">106</xref>]</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Diterpenes</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">Vitexolide A</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i014.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. aureus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Vitex vestita</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B107-antibiotics-09-00325" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">Acuminolide</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i015.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. aureus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Vitex vestita</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B107-antibiotics-09-00325" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">12-epivitexolide A</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i016.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. aureus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Vitex vestita</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B107-antibiotics-09-00325" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">8(17),12E,14-labdatrien-6,19-olide</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i017.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Salvia leriifolia</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B108-antibiotics-09-00325" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">8(17),11(Z),13(<italic>E</italic>)- trien-15,19-dioic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i018.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Caesalpinia decapetala</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B109-antibiotics-09-00325" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">(<italic>E</italic>)-8(17),12-labdadiene-15,16-dial</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i019.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>S. aureus</italic><break/>MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Zingiber montanum</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B110-antibiotics-09-00325" ref-type="bibr">110</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">16&#x003b1;-hydroxycleroda-3, 13 (14)-Z-dien-15, 16-olide (CD)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i020.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Polyathia longifolia</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B128-antibiotics-09-00325" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">Coleon U</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i021.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA<break/>VRE</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Plectranthus grandidentatus Plectranthus hereroensis</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B111-antibiotics-09-00325" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">7&#x003b1;-acetoxy-6&#x003b2;-hydroxyroyleanone</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i022.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA<break/>VRE</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Plectranthus grandidentatus Plectranthus hereroensis</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B111-antibiotics-09-00325" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">Horminone</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i023.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA<break/>VRE</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Plectranthus grandidentatus Plectranthus hereroensis</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B111-antibiotics-09-00325" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">7&#x003b1;,12-dihydroxy-17(15-16)abeo-abieta-8,12,16-triene-11,14-dione</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i024.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA<break/>VRE</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Plectranthus grandidentatus Plectranthus hereroensis</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B111-antibiotics-09-00325" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">16-Acetoxy-7&#x003b1;,12-dihydroxy-8,12-abietadiene-11,14-dione</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i025.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA<break/>VRE</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Plectranthus grandidentatus Plectranthus hereroensis</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B111-antibiotics-09-00325" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">Sincoetsin C</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i026.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA </td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Coleus blumei Benth.</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B112-antibiotics-09-00325" ref-type="bibr">112</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">ent-8 (14),15-pimaradien-3&#x003b2;-ol</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i027.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. aureus</italic>
<break/>
<italic>S. capitis</italic>
<break/>
<italic>S. haemolyticus</italic>
<break/>
<italic>E. faecalis</italic>
<break/>
<italic>E. epidermidis</italic>
<break/>
<italic>S. pneumoniae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Cell membrane disruption</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Viguiera arenaria</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B113-antibiotics-09-00325" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">rel-15(&#x003da;),16-epoxy-7R-hydroxypimar-8,14ene</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i028.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Plectranthus ernstii</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B114-antibiotics-09-00325" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="center" valign="middle" rowspan="1" colspan="1">rel-15(&#x003da;),16-epoxy-7-oxopimar-8,14-ene</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i029.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Plectranthus ernstii</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B114-antibiotics-09-00325" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">1R,11S-dihydroxy-8R,13R-epoxylabd-14-ene</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i030.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Plectranthus ernstii</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B114-antibiotics-09-00325" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">Isopimaric acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i031.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Pinus nigra</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B115-antibiotics-09-00325" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">ent-kaurenoic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i032.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>S. aureus</italic><break/><italic>S. capitis</italic><break/><italic>S. epidermidis</italic><break/><italic>S. haemolyticus</italic><break/><italic>E. faecalis</italic><break/>MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Cell membrane disruption</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Mikania glomerate</italic><break/><italic>Citrus reticulate</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B116-antibiotics-09-00325" ref-type="bibr">116</xref>,<xref rid="B117-antibiotics-09-00325" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">ent-pimaradienoic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i033.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. aureus</italic>
<break/>
<italic>S. capitis</italic>
<break/>
<italic>S. epidermidis</italic>
<break/>
<italic>S. haemolyticus</italic>
<break/>
<italic>E. faecalis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Cell membrane disruption</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Viguiera arenaria</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B116-antibiotics-09-00325" ref-type="bibr">116</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">semisynthetic derivative of 33 </td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i034.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. aureus </italic>
<break/>
<italic>S. capitis</italic>
<break/>
<italic>S. epidermidis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Cell membrane disruption</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B116-antibiotics-09-00325" ref-type="bibr">116</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ent-beyer-15-en-18-O-oxalate (BBN149)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i035.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>P. aeruginosa</italic>
<break/>
<italic>K. pneumoniae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Species:<break/><italic>Fabiana densa</italic> var <italic>ramulosa</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-antibiotics-09-00325" ref-type="bibr">118</xref>]</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Triterpenes</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b1;- Amyrin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i036.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MSSA<break/>MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B119-antibiotics-09-00325" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">37</td><td align="center" valign="middle" rowspan="1" colspan="1">Betulinic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i037.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MSSA<break/>MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B119-antibiotics-09-00325" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">38</td><td align="center" valign="middle" rowspan="1" colspan="1">Betulinaldehyde</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i038.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MSSA<break/>MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B119-antibiotics-09-00325" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">Oleanolic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i039.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA<break/>VRE</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Salvia officinalis</italic> (Sage)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B120-antibiotics-09-00325" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">Ursolic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i040.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA<break/>VRE<break/>NASEC<break/>NAREC</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Salvia officinalis</italic> (Sage)<break/><italic>Eucalyptus tereticornis</italic><break/><italic>Alstonia scholaris</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B120-antibiotics-09-00325" ref-type="bibr">120</xref>,<xref rid="B121-antibiotics-09-00325" ref-type="bibr">121</xref>,<xref rid="B122-antibiotics-09-00325" ref-type="bibr">122</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1">Butyl ester of ursolic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i041.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">NASEC<break/>NAREC</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B121-antibiotics-09-00325" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">42</td><td align="center" valign="middle" rowspan="1" colspan="1">Isopropyl ester of ursolic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i042.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">NASEC<break/>NAREC</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B121-antibiotics-09-00325" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">43</td><td align="center" valign="middle" rowspan="1" colspan="1">18&#x003b2;-glycyrrhetinic acid (18&#x003b2;-GA)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i043.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Glycyrrhiza glabra</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B131-antibiotics-09-00325" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">44</td><td align="center" valign="middle" rowspan="1" colspan="1">3&#x003b2;,6&#x003b2;,16&#x003b2;-trihydroxylup-20(29)-ene (CLF1)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i044.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. aureus</italic>
<break/>
<italic>E. coli</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Combretum leprosum</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B123-antibiotics-09-00325" ref-type="bibr">123</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45</td><td align="center" valign="middle" rowspan="1" colspan="1">16R-hydroxymollic</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i045.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">VRE<break/>MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Acalypha communis</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B124-antibiotics-09-00325" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46</td><td align="center" valign="middle" rowspan="1" colspan="1">15R-hydroxymollic</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i046.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">VRE</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Acalypha communis</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B124-antibiotics-09-00325" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">47</td><td align="center" valign="middle" rowspan="1" colspan="1">7&#x003b2;,16&#x003b2;-dihydroxy-1,23-dideoxyjessic acids</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i047.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">VRE</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Acalypha communis</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B124-antibiotics-09-00325" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">Aphagrandinoid D</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i048.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Acacia grandifolia</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B125-antibiotics-09-00325" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">49</td><td align="center" valign="middle" rowspan="1" colspan="1">3&#x003b2;-hydroxylanosta-9,24-dien-21-oic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i049.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. aureus</italic>
<break/>
<italic>P. mirabilis</italic>
<break/>
<italic>Salmonella</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Protorhus longifolia</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B126-antibiotics-09-00325" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">methyl-3&#x003b2;-hydroxylanosta-9,24-dien-21-oate</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="antibiotics-09-00325-i050.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. aureus</italic>
<break/>
<italic>P. mirabilis</italic>
<break/>
<italic>Salmonella</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Growth inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Species:<break/><italic>Protorhus longifolia</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B126-antibiotics-09-00325" ref-type="bibr">126</xref>]</td></tr><tr><td colspan="7" align="center" valign="middle" rowspan="1">
</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>MRSA, methicillin-resistant <italic>S. aureus</italic>; MSSA, methicillin sensitive <italic>S. aureus</italic>; VRE, vancomycin-resistant <italic>Enterococcus faecalis</italic>; NASEC, nalidixic acid-sensitive <italic>E. coli</italic>; NAREC, nalidixic acid-resistant <italic>E. coli</italic>.</p></fn></table-wrap-foot></table-wrap></floats-group></article>